Compositions and systems for modulating function / abundance and delivery of polypeptide payloads
Modulation hubs with multiple DRDs regulate polypeptide payloads, addressing toxicity and duration issues in biologics, ensuring precise and safe therapeutic delivery.
Patent Information
- Application Number
- CN202280070435.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-16
- Filing Date
- 2022-10-18
- Publication Date
- 2024-12-03
AI Technical Summary
Maintaining therapeutically effective levels of biologics, such as engineered T cells, is challenging due to potential toxicity and duration issues, hindering the widespread adoption of biologics like adoptive cell therapy.
Compositions and systems utilizing modulation hubs with multiple drug response domains (DRDs) to regulate the abundance and activity of payloads, such as polypeptides, through ligand-responsive connections, forming oligomers that provide improved control over payload function and dosage.
The system achieves precise regulation of payload activity, reducing off-state abundance and expanding the activity range, enhancing therapeutic efficacy and safety by minimizing toxicity and optimizing dosage.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 262,646, filed on October 18, 2021, and U.S. Provisional Application No. 63 / 342,443, filed on May 16, 2022, which are incorporated herein by reference in their entireties.
[0003] References to sequence listings
[0004] This application contains a sequence listing, which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. The sequence listing XML created on October 18, 2022 is named 108407-1354052-Oct 18.xml and is 691,346 bytes in size. Background Art
[0005] Biological products (biologics) as defined by the U.S. Food and Drug Administration include vaccines, blood and blood components, allergens, somatic cells, gene therapy, tissues and recombinant therapeutic proteins. Cells from the same subject (autologous), from subjects of the same species (homologous or allogeneic) or even from different species (heterogeneous) can be administered to subjects as biologics. In adoptive cell therapy ("ACT"), for example, T cells derived from subjects (or sometimes from different sources) are removed, genetically engineered to meet the specific needs of the same or different subjects, and then the cells are transferred back to the same or different subjects. However, the widespread adoption and success of biologics such as ACT currently still have some obstacles. Maintaining the therapeutically effective level of biologics administered to patients may be difficult because biologics may be expressed by engineered cells at toxic levels, or may exist or express at unacceptable durations. Therefore, it is necessary to regulate biologics to optimize the therapeutic benefits and promote the widespread adoption of biotherapies. Summary of the invention
[0006] The present disclosure relates to compositions and systems capable of regulating payload function, and methods for preparing and using the compositions and systems. Payload function can be regulated by modifying and / or regulating the abundance and / or activity of the payload, etc. Compositions and systems capable of modifying and / or regulating the activity and / or abundance of the payload, and methods for preparing and using the compositions and systems are described herein.
[0007] The present disclosure provides compositions referred to as "modulation hubs" comprising two or more drug response domains ("DRDs"). A DRD is a polypeptide that can modulate the abundance, availability, and / or activity of a payload under appropriate conditions (e.g., in response to a small molecule ligand). In some embodiments, the modulation hub comprises DRDs that are connected in series via covalent bonds. In such embodiments, the DRDs are directly or indirectly connected, for example, via a linker or hinge. In certain embodiments, the modulation hub comprises DRDs associated in an oligomer (also referred to as a multimeric fusion composition or fusion composition) of at least two DRD-oligomerization domain constructs, wherein the DRD-oligomerization domain constructs each comprise a DRD that is directly or indirectly connected to an oligomerization domain that is configured to promote oligomerization of the DRD-oligomerization domain construct. In some embodiments, wherein the oligomerization domain is a trimerization domain, the multimeric fusion composition includes three DRD-oligomerization domain constructs, thereby generating a regulatory hub having at least three DRDs and three trimerization domains. In any of the embodiments of the regulatory hub, the DRDs in the regulatory hub can all be the same, can all be different, or some can be the same and some can be different.
[0008] The present disclosure also provides a composition referred to as a polypeptide monomer, which includes an oligomerization domain configured to promote the oligomerization of a polypeptide monomer; and, at least one biologically active payload under appropriate conditions, or at least one drug response domain (DRD) responsive to a ligand. In some embodiments, an adjustable polypeptide monomer includes an oligomerization domain configured to promote the oligomerization of a polypeptide, at least one biologically active payload under appropriate conditions, and at least one drug response domain. In some such embodiments, such as those involving the same monomer, multiple monomers are oligomerized to form an oligomer comprising at least two payloads, the at least two payloads being operably connected to a regulatory hub, which in turn comprises at least two oligomerization domains and at least two DRDs. In other embodiments, such as those involving different monomers, the multiple monomers are oligomerized to form an oligomer comprising at least one payload, the at least one payload being operably connected to a regulatory hub, which in turn comprises at least two oligomerization domains and at least two DRDs. In certain embodiments, the regulation of effective load abundance and / or function in the obtained oligomer is improved compared with the same effective load in the control construct.For example, in certain embodiments, the activity level of effective load in the oligomer has the scope of the maximum activity level in the case of the basal activity level in the absence of ligand to the ligand in the presence of saturation amount, and the basal activity level of effective load in the oligomer is lower than the basal activity level of the same effective load in the control construct.In certain embodiments, the activity range of effective load in the oligomer is greater than the activity range of the same effective load in the control construct.Therefore, better dose response is provided in the presence of the small molecule ligand specific to DRD.
[0009] Also described herein is an engineered adjustable oligomer, which includes at least two polypeptide monomers, wherein each monomer includes an oligomerization domain configured to promote the oligomerization of the monomer.Also described herein is an engineered adjustable oligomer, which includes at least two polypeptide monomers, wherein each monomer includes an oligomerization domain configured to promote the oligomerization of the monomer, and at least one biologically active payload, or at least one DRD responsive to a ligand, or at least one biologically active payload and at least one DRD responsive to a ligand, provided that the oligomer includes at least one payload and at least two DRDs.In some embodiments, the oligomer includes at least two payloads and at least two DRDs.In some embodiments, the at least two payloads and the at least two DRDs are present in a ratio of 1:1.
[0010] In some embodiments, the engineered adjustable oligomer comprises at least two polypeptide monomers, wherein each monomer comprises an oligomerization domain, at least one effective load and at least one DRD, so that the oligomer comprises at least two effective loads operably connected to at least two DRDs. The oligomer can be formed by identical or different monomers, and each monomer in these monomers can have one or more DRDs and / or one or more effective loads. If a monomer has more than one DRD and / or more than one effective load, then if the oligomer is formed by all identical monomers and all DRDs and all effective loads in the monomer are identical, then multiple DRDs and multiple effective loads in the oligomer will be identical. Alternatively, if the oligomer is formed by different monomers with different effective loads and DRDs, or the oligomer is formed by the same monomer, but each monomer has multiple different effective loads and multiple different DRDs, then multiple DRDs and multiple effective loads in the oligomer will be different. In certain embodiments, an oligomer can have multiple identical effective loads and multiple different DRDs or multiple different effective loads and multiple identical DRDs.
[0011] These engineered adjustable oligomers are optionally hetero-oligomers comprising different DRDs, different effective loads, or different DRDs and different effective loads. In some hetero-oligomer embodiments, the oligomerization domain of one of the monomers is a hetero-oligomerization domain. In certain hetero-oligomer embodiments, the engineered adjustable oligomer comprises at least two polypeptide monomers constituting a first polypeptide monomer, a second polypeptide monomer, and a third polypeptide monomer, wherein the first polypeptide monomer and the second polypeptide monomer are identical, wherein each of the first polypeptide monomer and the second polypeptide monomer comprises an oligomerization domain and a DRD, and wherein the third polypeptide monomer comprises a hetero-oligomerization domain and an effective load.
[0012] In the embodiment of adjustable through engineered oligomer, the functional regulation of effective load in oligomer is improved compared with the same effective load in control construct.For example, in certain embodiments, the biological activity of effective load in the adjustable oligomer through engineering has the scope of maximum activity from the basic activity level in the absence of part to the part with saturation amount, and the basic activity level of effective load in oligomer is lower than the basic activity level of the same effective load in control construct.In some embodiments, the biological activity scope of effective load in oligomer is greater than the scope of the same effective load in control construct.
[0013] Also provided is a composition referred to as an engineered adjustable polypeptide, which has at least one payload with a biologically active level and a regulatory hub with at least two drug response domains (DRDs), wherein the regulatory hub is operably connected to the payload, and wherein the at least two DRDs are responsive to a ligand. The biological activity of the payload is regulated by the interaction of at least two DRDs of the regulatory hub with an effective amount of the ligand under appropriate conditions. In an embodiment, the functional regulation of at least one payload in the polypeptide is improved compared to the same payload in a control construct. For example, in some such embodiments, the activity range of the at least one payload is from the basal activity level in the absence of a ligand to the maximum activity in the presence of a saturated amount of a ligand, and the basal activity of the at least one payload is lower than the basal activity of the same payload in a control construct. As another example, the activity level range and dose response of at least one payload in an engineered adjustable polypeptide are optionally greater than the activity level range and dose response of the same payload in a control construct.
[0014] Provided herein are expressible nucleic acid constructs and vectors encoding one or more engineered adjustable polypeptide monomers that can be assembled into oligomers when expressed. Also provided are multiple nucleic acid constructs encoding the same or different engineered adjustable polypeptide monomers so that they are assembled into oligomers when expressed, wherein the oligomers comprise at least one payload operably connected to a regulatory hub comprising at least two DRDs. In an embodiment, the oligomer comprises at least two payloads operably connected to a regulatory hub comprising at least two DRDs, wherein the ratio of payload:DRD is 1:1. The present disclosure also provides nucleic acid constructs encoding engineered adjustable polypeptides.
[0015] Also provided are cells containing one or more expressible nucleic acid constructs or vectors. Optionally, the cell is a human cell, such as an immune cell.
[0016] The present disclosure also provides a system for modifying and / or regulating (hereinafter referred to as "regulating") the function of a payload, the system comprising a ligand and any of the mentioned polypeptides, oligomers, nucleic acid constructs, vectors or cells.
[0017] Disclosed herein is a method for regulating the function of a payload. In some embodiments, the regulating method includes engineering cells to express a payload that is operably connected to a regulatory hub comprising two or more DRDs. In such embodiments, the activity level of the payload in the absence of a ligand is reduced compared to a control cell (e.g., engineered to express a payload that is not dependent on DRDs). Optionally, the method includes contacting a cell with an effective amount of a ligand that is engineered to express a payload that is operably connected to a regulatory hub comprising two or more DRDs that respond to a ligand, so that the activity level of the payload increases relative to the basal activity level. Optionally, the two or more DRDs respond to the same ligand, and the method alternatively includes contacting the cell with a first selected dose of a ligand and a second selected dose of the same ligand, wherein the first selected dose of the ligand and the second selected dose result in a selected activity level of the payload, the first selected dose of the ligand and the second selected dose can be close to zero and up to a saturation dose, and can be the same or different. In embodiments in which the regulatory hub comprises a first DRD responsive to a first ligand and a second DRD responsive to a second ligand, and further in which the first DRD is different from the second DRD and the first ligand is different from the second ligand, these embodiments optionally include contacting the hub with a selected amount of the first ligand and a selected amount of the second ligand, wherein the first ligand is different from the second ligand.
[0018] Disclosed herein is a method for controlling the dosage or duration of an effective load administered to a subject, comprising administering to the subject one or more nucleic acid constructs, vectors or cells as described herein. The method optionally further comprises administering to the subject a selected amount of a ligand to deliver the selected activity of the effective load to the subject, thereby controlling the activity level of the effective load administered by one or more nucleic acid constructs, vectors or cells.
[0019] Also disclosed herein is a method for regulating the expression of a downstream target protein or peptide of a gene editing process. Such methods may include engineering a cell to express an engineered adjustable oligomer or polypeptide, the oligomer or polypeptide comprising a payload, such as a CAS9 protein or a transcription factor protein involved in controlling a gene editor, wherein the payload is operably connected to a regulatory hub. In such methods, a nucleic acid construct or vector as described herein is applied to a cell (in vivo, in vitro or in vitro) or a cell comprising the nucleic acid or vector is applied to a subject to regulate the expression of a target protein or peptide.
[0020] The embodiments identified are exemplary only and are therefore non-limiting. The details of one or more non-limiting embodiments of the present invention will be set forth in the accompanying drawings and the following description. After considering this disclosure, other embodiments of the present invention should be apparent to those of ordinary skill in the art. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 Polypeptide constructs useful for understanding the scope of the present disclosure are schematically illustrated. Figure 1 A depicts a construct that produced a control composition (a non-oligomerized polypeptide). Figure 1 B depicts an embodiment of a construct according to the present disclosure comprising a trimerization oligomerization domain that generates monomers that self-assemble into a trimerized tunable payload composition. Figure 1 C depicts the Figure 1 Engineered tunable payload compositions resulting from monomer association of B. Figure 1 D depicts an illustrative example of an engineered regulatable payload composition having a regulatory hub with two DRDs operably linked to a payload, according to certain embodiments of the present disclosure. Figure 1 The embodiment of D lacks the transmembrane region, thus showing an embodiment of an intracellular polypeptide.
[0022] Figure 2 Various construct monomers are schematically illustrated, each of which has a payload operably connected to an oligomerization domain and a DRD. When expressed, the construct monomers self-assemble via the oligomerization domain and form a multimeric regulatable polypeptide (an engineered regulatable polypeptide) according to an embodiment of the present disclosure. The degree of multimerization is generally determined by the selection of the oligomerization domain. Thus, for example, constructs with CD40L extracellular domain (ECD), collagen 18, langerin, collectin 7, DAP12, and 4-1BB1 oligomerization domains tend to form trimerized regulatable payload compositions, while constructs with VASP oligomerization domains tend to form tetrameric regulatable payload compositions, and constructs with phospholamban oligomerization domains tend to form pentameric regulatable payload compositions.
[0023] Figure 3Schematic representation of the polypeptide components encoded in the following constructs is shown: IL12-217 (SEQ ID NOs: 125 and 126), IL12-223 (SEQ ID NOs: 127 and 128), IL12-241-252 (SEQ ID NOs: 129-152), IL12-254-262 (SEQ ID NOs: 153-170), CD19-IL12-192 (SEQ ID NOs: 123 and 124), CD19-IL12-297-316 (SEQ ID NOs: 171-210), and CD19-IL12-319-332 (SEQ ID NOs: 211-238). Although the schematic diagram of CD19-IL12-192 (SEQ ID NO: 123 and 124), CD19-IL12-297-316 and CD19-IL12-319-332 does not show the CD19-CAR sequence at the beginning of the construct, the sequence is separated by the P2A sequence and is included in the sequence table of each construct. IL12-217 to IL12-262 include mCherry separated by the P2A sequence in the construct, while IL12-192 and IL12-297 to IL12-332 include CD19-CAR at the beginning of the construct. These additional domains are present and included in the sequence table of each construct. Some constructs in this construct encode control compositions. The control composition referred to as a "control construct" is a composition (e.g., IL12-217 and IL12-223) encoding polypeptides and oligomers lacking oligomerization domains and / or lacking multiple DRDs, as defined in the definition section of this specification. Control compositions referred to as "DRD controls" are those compositions that lack functional DRDs. Examples of DRD controls are constructs with wild-type (wt) DRDs, such as CA2 (wt). Other constructs described herein are polypeptides with multiple DRDs and polypeptide monomers that can self-assemble into adjustable oligomers according to embodiments of the present disclosure. Other constructs encode polypeptide monomers that can self-assemble into adjustable polypeptides according to embodiments of the present disclosure.
[0024] Figure 4A representative procedure for in vitro characterization and / or validation of CA2-regulated membrane-bound IL12 ("mbIL12") expression in T cells is shown. On day 0, peripheral blood T cells were stimulated with Dynabeads (T-expander CD3 / CD28). On day 1, cells were transduced with a lentiviral vector. On day 6, flow cytometry was used to assess the transduction efficiency of the cells. As a readout of cell transduction, CD19-CAR expression was detected using a CD19-Fc reagent and subsequently a fluorescently labeled anti-human Fc antibody. On day 8, a normalized number of transduced (CAR+) cells were plated on a 96-well plate and treated with acetazolamide (ACZ) or an equivalent volume of DMSO vehicle control in the absence or presence of antigen restimulation. Stimulation conditions were human Immunocult soluble CD3 / CD28 reagent (StemCell Technologies, catalog number 10971), K562 cells stably expressing the CAR antigen CD19 at an effector to target (E: T) ratio of 1: 1 (Lozzio and Lozzio (1975) Blood 45: 321-334), or parental control K562 cells. At day 9, mbIL12 expression on transduced T cells was analyzed.
[0025] Figure 5A -C provides a flow cytometry graph showing surface expression (abundance) of IL12 in HEK cells transfected with control and inventive constructs, demonstrating modulation of IL12 function in HEK cells engineered according to embodiments of the present disclosure. The construct includes mCherry (not shown).
[0026] Figure 6 is a graph showing the geometric mean fluorescence intensity ("MFI") indicating IL12 surface expression (abundance) in Jurkat cells transduced with a control (217) and constructs of the invention (241, 243, 245, 247, 248, 254, 256 and 258, including mCherry), demonstrating modulation of IL12 function in Jurkat cells according to embodiments of the present disclosure.
[0027] Figure 7 Figure 2 shows the levels of IL12p70 secreted from T cells transduced with control (192 and 223) and constructs of the invention (241, 245, 247, 256 and 260). Figure 6 The results in Jurkat cells of , which demonstrate the regulation of IL12 according to embodiments of the present disclosure. Approximately equally transduced cells (15-25%) were plated in equal numbers. Constructs included mCherry (not shown), except CD19 IL12-192.
[0028] Figure 8 Is a graph showing the geometric MFI of IL12 abundance on the surface of CAR-T cells transduced with control (192) and constructs of the invention (241, 245, 247, 256, 260), demonstrating modulation of IL12 function and demonstrating that the basal off-state levels of the invention are lower than those of the control constructs. The constructs include mCherry (not shown).
[0029] Fig. 9 Schematic diagrams of polypeptide monomer constructs according to embodiments of the present disclosure are provided. CD19-IL12-302-306 (SEQ ID NOs: 181-189) and CD19-IL12-319-329 (SEQ ID NOs: 211-231). Although included in the test constructs, the CD19-CAR sequence was not Fig. 9 Shown in. TM, transmembrane domain. Cyto, cytoplasmic tail.
[0030] Fig. 10A The MFI representing membrane-bound IL12 expression in activated T cells transduced with constructs of the invention (CD19-IL12-302-306 and CD19-IL12-319-329) and control constructs (CD19-IL12-192, empty vector (EV), untransduced (UT)) is shown, demonstrating that the basal disconnection state of cells engineered with the invention is lower than that of the control construct. Results for CD19-CAR T cells are shown.
[0031] Fig. 10B Shown is a representative Fig. 10A MFI of membrane-bound IL12 abundance (determined by CD19-CAR positivity) in non-activated CAR T cells transduced with the same construct as shown in , which again demonstrates that the basal off-state of cells engineered with the present invention is lower compared to the control construct.
[0032] Fig.11A In 20 hours, 40,000 Fig. 10A Figure 3 shows the abundance of IL12 shed by activated CD-19 CAR+ engineered T cells into 200 μl of culture medium, demonstrating that regulation is largely maintained and consistent with Fig. 10A The results are comparable.
[0033] Fig. 11B In 20 hours, 40,000 Fig. 10B Figure 3 shows the abundance of IL12 shed by CD-19 non-activated CAR+ cells into 200 μl of culture medium, demonstrating that regulation is largely maintained and consistent with Fig. 10B The results are comparable.
[0034] Fig.12 Schematic diagram of the procedure for testing IL12 abundance and activity by measuring phosphorylation of STAT4.
[0035] Fig.13A The MFI detected from pSTAT expression in the NK bystander assay as described in Example 7 is shown and indicates that modulation of the shed portion of the constructs according to embodiments of the present disclosure is functionally important.
[0036] Fig. 13B A standard curve of pSTAT MFI values versus IL12 concentration is shown.
[0037] Fig.14 Schematically illustrated are additional embodiments of polypeptide monomer constructs each comprising a payload, a DRD, and an oligomerization domain, which can self-assemble into oligomers according to the present disclosure.
[0038] Fig.15 is a stylized representation of regulatable payload compositions (showing IL12 as an exemplary payload or indicating a protein of interest (POI) as a general payload and showing CA2 as an exemplary DRD or DRD1-3 as general DRDs) produced by cells engineered to express nucleic acid constructs according to embodiments of the present disclosure.
[0039] Fig.16 Exemplary programmed nucleic acid constructs comprising a payload and a regulatory hub comprising more than one DRD are illustrated.
[0040] Fig.17 are examples of monomer constructs that assemble into regulatable oligomers and corresponding regulatable oligomers according to embodiments of the present invention.
[0041] Fig.18 Schematically illustrated are methods for making the engineered regulatable constructs of the present disclosure by selecting a DRD / ligand pair, designing a polypeptide or oligomer for appropriate function, providing expression control, and by providing efficient delivery to target cells. Fig.18 SEQ ID NOs: 243 and 244 are disclosed respectively in order of appearance.
[0042] Fig.19 An exemplary process for designing engineered regulatable polypeptides comprising membrane-tethered cytokines with sufficient dynamic range is shown.
[0043] Fig. 20Schematic illustration of exemplary monomer constructs used to create heterotrimers with a single payload and multiple DRDs. Each construct contains DAP12 and NKG2C hetero-oligomerization domains.
[0044] Fig.21A Histograms of cellular IL12 levels in the presence of acetazolamide (+) or DMSO (-) are shown. Fig. 21B Cells are transduced with the nucleic acid depicted in the monomer.
[0045] Fig. 21B Is used to depict Fig. 20 Schematic diagram of the assembly and oligomeric states of the monomers (top) and exemplary heterodimers (IL12-267 is a control construct with only one DRD) depicted in . IL12-266 and 268 show engineered regulatable homodimers (IL12-266) and heterotrimers (IL12-268) in which the regulatory hub contains multiple DRDs.
[0046] Fig. 21C Shown are the fold changes in IL12 geometric MFI following addition of drug to each of IL12-266, 267, and 268. As the transduced cells progressed from monomers, dimers, to trimers, they displayed a pattern of increasing fold regulation.
[0047] Fig. 22 is a graph showing surface IL23 expression on CD19 CAR+ cells plotted using Prism software.
[0048] Fig.23 is a graph showing IFNα expression on CD19 CAR+ cells plotted using Prism software.
[0049] Fig.24 is a graph showing IL2 expression on CD19 CAR+ cells plotted using Prism software.
[0050] Fig.25 A schematic diagram illustrating the experimental design for determining IL18 expression is shown.
[0051] Fig.26 is a schematic diagram showing the experimental design for determining IFNγ levels.
[0052] Fig. 27 is a graph showing IL18 expression in unactivated T cells transformed with unregulated IL18 constructs.
[0053] Fig.28 is a graph showing IL18 expression in activated T cells transformed with unregulated IL18 constructs.
[0054] Fig.29 is a graph showing interferon gamma (IFNγ) expression in naive T cells transformed with an unregulated IL18 construct.
[0055] Fig.30 is a graph showing interferon gamma (IFNγ) expression in IL15-treated T cells transformed with an unregulated IL18 construct.
[0056] Fig.31 is a graph showing IL18 expression in non-activated T cells transformed with regulated IL18 constructs.
[0057] Fig.32 is a graph showing IL18 expression in activated T cells transformed with regulated IL18 constructs.
[0058] Fig.33 is a graph showing IL18 expression at day 8 in non-activated T cells transformed with regulated IL18 constructs.
[0059] Fig.34 is a graph showing IL18 expression at day 10 in non-activated T cells transformed with regulated IL18 constructs.
[0060] Fig.35 is a graph showing IL18 expression at day 8 in activated T cells transformed with regulated IL18 constructs.
[0061] Fig.36 is a graph showing IFNγ expression in T cells treated with 20 ng / mL IL15 and transformed with modulated IL18 constructs.
[0062] Fig.37 is a graph showing IFNγ expression in T cells treated with 20 ng / mL IL15 and transformed with modulated IL18 constructs.
[0063] Fig.38 is a bar graph showing IL18 expression in T cells transformed with regulated IL18 constructs in the presence and absence of acetazolamide (ACZ).
[0064] Fig.39 is a bar graph showing the geometric mean fluorescence intensity (GMFI) of T cells expressing membrane-bound IL18 in the presence and absence of ACZ.
[0065] Fig.40 is a bar graph showing IL18 expression in T cells transformed with regulated IL18 constructs in the presence and absence of ACZ.
[0066] Fig.41 1 is a graph showing IL18 expression and shedding in cells that were not transformed (UT) or transformed with IL18-064 in the presence and absence of ACZ. The first three columns are non-activated cells, and the last three columns are activated cells. In unactivated cells with IL18-064 treated with ACZ, IL18 shedding with ACZ increased by 1.7 times. In activated cells with IL18-064 treated with ACZ, IL18 expression increased by 3.1 times, and IL18 shedding increased by 2.1 times.
[0067] Fig.42 1 is a graph showing IL18 expression and shedding in cells that were not transformed (UT) or transformed with IL18-066 in the presence and absence of ACZ. The first three columns are non-activated cells, and the last three columns are activated cells. In unactivated cells with IL18-066 treated with ACZ, IL18 shedding with ACZ increased by 2.0 times. In activated cells with IL18-066 treated with ACZ, IL18 expression increased by 3.1 times, and IL18 shedding increased by 2.6 times.
[0068] Fig.43 : is a graph showing IL18 expression and shedding in cells that were not transformed (UT) or transformed with IL18-069 in the presence and absence of ACZ. The first three columns are non-activated cells, and the last three columns are activated cells. In activated cells with IL18-069 treated with ACZ, IL18 expression increased 1.9-fold, and IL18 shedding increased 1.3-fold.
[0069] Fig.44 : is a graph showing IL18 expression and shedding in cells that were not transformed (UT) or transformed with IL18-070 in the presence and absence of ACZ. The first three columns are non-activated cells, and the last three columns are activated cells. In activated cells with IL18-070 treated with ACZ, IL18 expression increased 1.8-fold, and IL18 shedding increased 1.1-fold.
[0070] Fig.45 : is a graph showing IL18 expression and shedding in cells that were not transformed (UT) or transformed with IL18-071 in the presence and absence of ACZ. The first three columns are non-activated cells, and the last three columns are activated cells. In activated cells with IL18-071 treated with ACZ, IL18 expression increased 1.8-fold, and IL18 shedding increased 1.2-fold.
[0071] Fig.46 is a bar graph showing IL18 expression in T cells transformed with the IL18-048 construct and treated with 20 ng / mL IL15 in the presence and absence of ACZ.
[0072] Fig.47 is a bar graph showing IL18 expression in T cells transformed with the IL18-064 construct and treated with 20 ng / mL IL15 in the presence and absence of ACZ.
[0073] Fig.48 is a bar graph showing IL18 expression in T cells transformed with the IL18-066 construct and treated with 20 ng / mL IL15 in the presence and absence of ACZ.
[0074] Fig.49 is a bar graph showing IL18 expression in T cells transformed with the IL18-069 construct and treated with 20 ng / mL IL15 in the presence and absence of ACZ.
[0075] Fig.50 is a bar graph showing IL18 expression in T cells transformed with the IL18-070 construct and treated with 20 ng / mL IL15 in the presence and absence of ACZ.
[0076] Fig.51 is a bar graph showing IL18 expression in T cells transformed with the IL18-071 construct and treated with 20 ng / mL IL15 in the presence and absence of ACZ.
[0077] Fig.52 is a bar graph showing IL18 expression and shedding in T cells transformed with the IL18-064 construct in the presence and absence of ACZ.
[0078] Fig.53 is a bar graph showing IL18 expression and shedding in T cells transformed with the IL18-066 construct in the presence and absence of ACZ.
[0079] Fig.54 is a bar graph showing IL18 expression and shedding in T cells transformed with the IL18-048 construct in the presence and absence of ACZ.
[0080] Fig.55 is a graph showing IL18 expression by Jurkat cells in the presence and absence of ACZ.
[0081] Fig.56 is a graph showing surface recognition of IL12 in resting T cells.
[0082] Fig.57 is a graph showing shedding of IL12 in resting T cells transformed with control and experimental IL12 constructs.
[0083] Fig.58 It is a graph showing the shedding IL12 activity on NK cells.
[0084] Fig.59 It is a diagram showing the surface recognition of IL12 in activated T cells stimulated with CD3 / CD28.
[0085] Fig.60 is a graph showing the shedding of IL12 in activated T cells transformed with control and experimental IL12 constructs.
[0086] Fig.61 It is a graph showing the shedding IL12 activity on NK cells.
[0087] Fig.62 is a schematic diagram showing the experimental design for in vivo studies of IL12 modulation.
[0088] Figures 63A-63C is a diagram showing that ACZ regulates mbIL12 on CD19-CART in vivo.
[0089] Fig.64 is a graph showing that oligomerization constructs shedding IL12 in plasma are regulated by ACZ with non-zero off-states.
[0090] Fig.65 is a schematic diagram showing the design of the scRaji solid tumor model study.
[0091] Fig.66 is a graph showing tumor growth in the CAR alone or empty vector (EV) control group.
[0092] Fig.67 is a graph showing tumor growth in mice administered CAR-T cells with or without ACZ.
[0093] Fig.68 is a graph showing that infusion of IL12-expressing CAR-T cells exhibits delayed but robust regulated anti-tumor activity at suboptimal CAR-T cell doses.
[0094] Fig.69A and Fig.69B is a diagram showing that regulatory hubs allow ACZ-driven control of IL12 in plasma.
[0095] Fig.70A and Fig.70B is a graph showing that the mbIL12 regulatory hub allows for control of systemic IFNγ. Notably, by day 14, IFNγ levels returned to baseline for all mbIL12 constructs except for the one that was turned on with ACZ.
[0096] Fig.71A and Fig.71B is a graph showing that the mbIL12 regulatory hub allows control of IFNγ in tumors (day 7 after ACT).
[0097] Fig.72A and Fig.72B Figure 2 is a graph showing that mbIL12 regulates central enhancement of IFNγ production relative to localization to tumors. Regulatory mbIL12 has a higher ratio of IFNγ in tumors compared to constitutive mbIL12, which may be due to the activation dependence of IL12 regulation.
[0098] Fig.73 This is a graph showing that IL12 in the on state leads to increased activation of dendritic cells.
[0099] Fig.74 It is a graph showing that the on-state IL12 leads to increased activation of MHCII monocytes.
[0100] Fig.75 is a graph showing the percentage of tumor-associated macrophages reduced by IL12.
[0101] Fig.76 is a graph showing the percentage of TAMs with a TAM phenotype that is reduced by IL12.
[0102] Fig.77 It is a graph showing that IL12 skews TAMs toward an M1-like phenotype.
[0103] Fig.78 is a graph showing that secreted IL12 increases PD-L1 more than mbIL12 in multiple cell types and tissues.
[0104] Fig.79 is a flow cytometric readout showing IL12 expression in Jurkat cells transduced with IL12 constructs in the presence or absence of VDF 10 μM for 24 hours.
[0105] Fig.80 are images showing the percentage of Jurkat cells expressing IL12 in the presence or absence of VDF 10 μM for 24 hours.
[0106] Fig.81 is a graph showing the geometric MFI indicating the abundance of IFNα on the surface of tumor infiltrating lymphocytes.
[0107] Fig.82 is a graph showing IFNα regulation in the presence of ACZ.
[0108] Fig.83is a schematic diagram showing T cell transduction experiments using constructs containing IL15 and IFNα.
[0109] Fig.84 It is a diagram showing the enrichment of mbIL15 on the surface of T cells over time. Patterned bars refer to +ACZ, and solid bars refer to +vehicle. The first bar group (solid bars and subsequent patterned bars) is for cells containing IFNα-003, the next bar group is for cells containing IFNα-007, the third bar group is for cells containing IFNα-015, the fourth bar group is for cells containing IFNα-016, and the fifth and last bar group is for cells containing IFNα-018.
[0110] Fig.85 It is a figure showing that IFNα is regulated by about 20 times in IFNα-016 and IFNα-018 constructs. Patterned bars refer to +ACZ, and solid bars refer to +vehicle. The first bar group (solid bars and subsequent patterned bars) is for cells containing IFNα-003, the next bar group is for cells containing IFNα-007, the third bar group is for cells containing IFNα-015, the fourth bar group is for cells containing IFNα-016, the fifth bar group is for cells containing IFNα-018, and the sixth bar group and the last bar group are for control cells containing empty vectors.
[0111] Fig.86 is a schematic diagram showing the experimental layout of Jurkat cell transduction.
[0112] Fig.87 is a bar graph showing the percentage of cells expressing IL15 after transduction with IL18 constructs. 300 μl of virus generated 70% to 90% of transduced cells, 100 μl of virus generated 40% to 65% of transduced cells and 33 μl of virus generated 7% to 33% of transduced cells.
[0113] Fig.88 is a graph showing that modulation of membrane-bound IL18 was observed when constructs containing VEGFR were used.
[0114] Fig.89 It is a bar graph showing 10-fold regulation (geometric MFI) of film IL18 observed in IL18-080 construct. Bar refers to the left y-axis, which shows mbIL18 expression. Bottom numbers show mbIL18 change multiples. Circles refer to the right y-axis, which shows IL18 released in the culture medium. Top numbers show the change multiples of shedding IL18.
[0115] Fig.90: The modulation of the percentage of IL18 on the cell membrane was more pronounced in the IL18-080 construct. The numbers show the fold change of the percentage of mbIL18. IL18-081 and -082 showed very high fold changes, which is due to the very low percentage values of IL18 in the off state.
[0116] Fig.91 are images showing small scale viral transduction in Jurkat cells for SOX2 constructs. DETAILED DESCRIPTION
[0117] The present disclosure provides compositions and systems for regulatory control of payloads ("regulatory compositions and systems"). The regulatory compositions according to the present disclosure include a regulatory hub, wherein the regulatory hub includes at least two drug response domains (DRDs) that are responsive to a ligand; and, at least one payload operably linked to the regulatory hub. The regulatory composition also includes an engineered adjustable polypeptide monomer (or polypeptide monomer, or simply monomer); an engineered adjustable oligomer (or adjustable oligomer, or simply oligomer); and an engineered adjustable polypeptide (or regulated polypeptide, or simply polypeptide). The adjustable oligomer is formed by an adjustable monomer, and the adjustable oligomer and the adjustable polypeptide include at least one payload operably linked to the regulatory hub. The regulatory system according to the present disclosure includes a regulatory composition and a stabilizing ligand.
[0118] In some embodiments, the present disclosure is used to achieve regulation of biologically active payloads. For example, the present disclosure describes improved drug response domain (DRD)-based regulation of payloads by improving control of the off-state of the payload (i.e., reducing the abundance or availability of the payload in the absence of a ligand) and / or optimizing its regulation range compared to DRD regulation systems comprising a single DRD.
[0119] Without intending to be limited by theory, DRD is considered to be an unstable polypeptide that degrades in the absence of its corresponding stabilizing ligand (also referred to as a paired ligand or ligand), but the stability of the polypeptide is rescued by binding to a stabilizing ligand. Since the binding of the ligand to DRD is reversible, the subsequent removal of the ligand causes DRD to unfold, become unstable, and ultimately be marked for degradation by the ubiquitin-proteasome system ("UPS"). Therefore, it is believed that when DRD is operably connected to a payload, the entire structure (i.e., DRD plus payload) itself becomes unstable and is degraded by the UPS. However, in the presence of a paired ligand, the construct is stable and the payload is still available. Further, it is believed that the conditional nature of DRD stability allows rapid and non-interfering conversion from a stable polypeptide to an unstable UPS substrate, and can facilitate the regulation of payload activity levels, and / or the regulation of payload activity levels. The basic discovery that leads to improved regulatory control is that multiple DRDs associated together in a regulatory hub cause the payload to have a lower disconnected state than the same payload operably connected to a single DRD. That is, in the absence of a ligand, increasing the density of DRDs (eg, having multiple DRDs) is believed to result in a decrease in the abundance or availability of a payload compared to a payload that is only operably linked to a single DRD.
[0120] Payload should be understood to include one or more polypeptides having one or more functions (such as one or more biological activities) that need to be regulated. Payload includes many types of therapeutically important polypeptides (proteins and peptides), such as type I / II membrane proteins, cytokines, intracellular proteins, secreted proteins, CAS9 proteins and transcription factor proteins.
[0121] Because the abundance and availability of the payload are related to the activity of the payload, for the purposes of this disclosure, the terms "abundance," "availability," "activity," and the phrases "abundance and / or activity" (and similarly, "abundance level," "availability level," "activity level," and "abundance and / or activity level") are used interchangeably throughout this disclosure and are generally referred to as "activity," unless otherwise clearly indicated or illogical in context. Further, measurements of abundance or availability are used as surrogates for activity levels and can be used herein to reflect activity levels. Thus, a change in the abundance or availability of the payload in the presence of an effective amount of a ligand compared to the absence of the ligand optionally serves as a surrogate for measuring a change in activity level.
[0122] Engineered Regulatable Peptides
[0123] Provided herein are engineered regulatable polypeptides having at least one payload and a regulatory hub having at least two drug response domains (DRDs), wherein the regulatory hub is operably connected to the payload, and wherein the at least two DRDs are responsive to a ligand. The at least two DRDs may be identical or different, and optionally the at least two DRDs are responsive to the same ligand. For example, in certain embodiments, the regulatory hub comprises three DRDs, wherein the three DRDs are responsive to the same ligand. The at least one payload has biological activity, and the biological activity of the payload is regulated by the interaction of the two or more DRDs (e.g., 2, 3, 4 or more, which are responsive to the same or different ligands) with an effective amount of ligands. In the case of multiple different DRDs that respond to different ligands, it should be understood that the "ligand" mentioned means "multiple ligands". The activity level of the at least one payload ranges from the basal activity level in the absence of a ligand to the maximum activity level in the presence of a saturated amount of ligand, and the basal activity level of the payload in the regulatable polypeptide is lower than the basal activity level of the same payload in the control construct. The saturation amount of a ligand refers to any amount of a ligand that is at or above the maximum abundance and / or activity of the effective load. For example, the activity level of the at least one effective load ranges from the basal activity level in the absence of the ligand to the maximum activity level in the presence of a saturation amount of the ligand, and the activity level range of the effective load in the adjustable polypeptide is greater than the activity level range of the same effective load in the control construct. In some embodiments, the at least one effective load is a plurality of effective loads (e.g., two or three effective loads that are identical or different from each other). Thus, for example, in some embodiments, the at least one effective load is three effective loads and the at least two DRDs are three DRDs, wherein the three effective loads are identical and the three DRDs are responsive to the same ligand. In certain embodiments, the at least one effective load is a useful load, and the at least two DRDs are three DRDs that respond to the same ligand. Figure 1 D depicts an illustrative example of an engineered regulatable polypeptide having a regulatory hub with two DRDs operably linked to a payload.
[0124] Peptide monomers and engineered tunable oligomers
[0125] Provided herein are engineered polypeptide monomers and engineered adjustable oligomers of at least two engineered polypeptide monomers. The oligomer comprises at least one effective load operably connected to a regulatory hub comprising two or more DRDs. The effective load has biological activity, and the biological activity of the effective load is regulated by the interaction of two or more DRDs (e.g., 2, 3, 4 or more, which respond to the same or different ligands) and an effective amount of ligands.
[0126] In some embodiments, the monomer comprises at least one payload, an oligomerization domain (e.g., a dimerization domain, a trimerization domain, a tetramerization domain, a pentamerization domain, or a hexamerization domain) configured to promote oligomerization of the monomer, and at least one DRD responsive to a ligand, wherein the at least one payload is operably linked to the at least one DRD. In certain embodiments, the monomer comprises an oligomerization domain; and, at least one payload, or at least one DRD, or at least one payload and at least one DRD, provided that when at least two or more monomers oligomerize to form an oligomer, the resulting oligomer comprises at least one payload operably linked to a regulatory hub comprising at least two DRDs.
[0127] The oligomer according to the present disclosure is a polymeric association of at least two engineered adjustable polypeptide monomers. The monomers of the oligomer are associated by an oligomerization domain. The oligomer can be, for example, a dimer produced by the association of monomers via a dimerization domain; or it can be a trimer produced by the association of monomers via a trimerization domain; or it can be a tetramer produced by the association of monomers via a tetramerization domain; or it can be a pentamer produced by the association of monomers via a pentamerization domain; or it can be a hexamer produced by the association of monomers via a hexamerization domain. In each case, the oligomer can be produced by the same or different monomers. Therefore, the one or more effective loads of each monomer in the monomer are the same or different, and the DRD of each monomer in the monomer is the same or different. Thus, for example, an oligomer can be an association of three monomers, wherein each monomer comprises the same payload, oligomerization domain, and DRD, and thus the oligomer comprises the same first, second, and third payloads, and a regulatory hub comprising the first, second, and third DRDs that are responsive to the same ligand.
[0128] Therefore, the present invention also provides an engineered adjustable oligomer comprising at least two polypeptide monomers, wherein each monomer comprises an oligomerization domain and at least one effective load or a DRD, wherein the oligomer comprises at least one effective load operably connected to at least two DRDs, wherein the at least one effective load has biological activity, wherein the at least two DRDs are responsive to a ligand. Optionally, the oligomer is a hetero-oligomer, wherein at least two polypeptide monomers of the hetero-oligomer each comprise an oligomerization domain, and wherein in some embodiments, the oligomerization domain of one polypeptide monomer in the polypeptide monomer comprises a hetero-oligomerization domain. Optionally, the DRDs in the hetero-oligomer are the same or different. Optionally, the at least two DRDs are responsive to the same ligand. For example, an engineered adjustable hetero-oligomer comprises a first polypeptide monomer, a second polypeptide monomer, and a third polypeptide monomer, wherein the first polypeptide monomer and the second polypeptide monomer are the same, wherein each of the first polypeptide monomer and the second polypeptide monomer comprises a DRD, and wherein the third polypeptide monomer comprises a hetero-oligomerization domain and an effective load. Fig. 21B Depicted are heterotrimers comprising one payload and two or three DRDs, as well as control constructs with only one DRD. In certain hetero-oligomer embodiments, each monomer comprises the same oligomerization domain, but comprises different payloads and / or DRDs. A hetero-oligomeric construct can similarly comprise a first monomer and a second monomer, each comprising a DRD and a payload, and a third monomer comprising a DRD but not containing a payload. However, an engineered adjustable hetero-oligomer can have a payload:DRD ratio of 1:1.
[0129] Multiple payloads in an oligomer can be the same or different, but in embodiments, each payload in the one or more payloads has biological activity under appropriate conditions. In some such embodiments, the activity level of each payload in an oligomer has a range of maximum activity from the basal activity level in the absence of a ligand to the presence of a saturated amount of a ligand, and the basal activity of each payload of an oligomer is lower than the basal activity of the same payload in a control construct. In some embodiments, the activity range of each payload in an oligomer is greater than the activity range of the same payload in a control construct. See, for example, Examples 3-5 below.
[0130] Also provided are oligomers comprising at least two polypeptide monomers, wherein each monomer comprises at least one payload, an oligomerization domain and a DRD, wherein the oligomer comprises at least two payloads operably linked to at least two DRDs, wherein the at least two payloads have a level of biological activity, wherein the DRDs are responsive to a ligand, and wherein in some embodiments, the at least two payloads and the at least two DRDs are present in a 1: 1 ratio. In certain embodiments, the payload is present in the oligomer at a payload:DRD ratio of 1:2, 1:3, 2:3, 1:4, 3:4, 1:5, 2:5, 3:5, or 4:5, or at a DRD:payload ratio of 2:1, 3:1, 3:2, 4:1, 4:3, 5:1, 5:2, 5:3, or 5:4 (provided that the oligomer always comprises at least two DRDs). In some embodiments, the at least two DRDs may be identical or different, the at least one payload is a plurality of payloads, the plurality of payloads may be identical or different, or the plurality of DRDs may be different but responsive to the same ligand. The oligomer may comprise, for example, a regulatory hub comprising a first DRD, a second DRD, and a third DRD that are responsive to the same or different ligands, and the first payload, the second payload, and the third payload that are identical or different. In some embodiments, the first DRD, the second DRD, and the third DRD are responsive to the same ligand, and the first payload, the second payload, and the third payload are identical. The activity level of each payload in the oligomer has a range of maximum activity from the basal activity level in the absence of the ligand to the presence of a saturated amount of the ligand, and wherein the basal activity of each payload in the oligomer is lower than the basal activity of the same payload in the control construct. Optionally, the range of activity levels of payloads in the oligomer is greater than the range of activity levels of the same payload in the control construct.
[0131] Figure 1 Exemplary polypeptide constructs useful for understanding the scope of the present disclosure are depicted. Figure 1 A depicts a control construct with payload, hinge region, and DRD. Figure 1 B depicts a polypeptide monomer construct according to the disclosure comprising an oligomerization domain that produces monomers that self-assemble into oligomers according to the disclosure. Figure 1 C depicts the Figure 1 Engineered tunable oligomers generated by monomer association of B.
[0132] Figure 2Schematic diagrams of various polypeptide monomer constructs are shown, each of which has a payload operably linked to an oligomerization domain and a DRD. When expressed, the polypeptide monomers self-assemble via the oligomerization domain and form a multimeric adjustable polypeptide (an engineered adjustable payload composition, when it is formed by monomers, also referred to as an oligomer) according to an embodiment of the present disclosure. The degree of multimerization is generally determined by the selection of the oligomerization domain. Thus, for example, constructs with CD40L ECD, collagen 18, lectin, DAP12, and 41BB1 oligomerization domains tend to form trimerized adjustable payload compositions, while constructs with VASP oligomerization domains tend to form tetrameric adjustable payload compositions, and constructs with phospholamban oligomerization domains tend to form pentameric adjustable payload compositions.
[0133] Figure 3 Schematic representations of the polypeptide components of the following constructs are shown: IL12-217 (SEQ ID NOs: 125 and 126), IL12-223 (SEQ ID NOs: 127 and 128), IL12-241-262 (SEQ ID NOs: 129-170), CD19-IL12-192 (SEQ ID NOs: 123 and 124), CD19-IL12-297-316 (SEQ ID NOs: 171-210), and CD19-IL12-319-332 (SEQ ID NOs: 211-238). Some of the constructs are control constructs of the adjustable composition and lack the oligomerization domain (e.g., IL12-217, IL12-223, and CD19-IL12-192), resulting in the payload being operably linked to only a single DRD; others are control constructs of the DRD and contain wild-type CA2 polypeptide in place of mutant CA2 (242, 246, 249, 252, 255, 257, 259, 262, 297), while others (e.g., IL12-241) are polypeptide monomers that can self-assemble into adjustable payload compositions according to embodiments of the present disclosure.
[0134] Monomers and Regulatable Peptide Components
[0135] The example components (building blocks) of the engineered monomers and the engineered adjustable polypeptides described herein that associate to form adjustable engineered oligomers are mentioned throughout the disclosure and provided below. As described herein, the monomers include at least an oligomerization domain and: a payload, or a DRD, or a payload and a DRD. Also as described herein, oligomers and polypeptides include one or more payloads and a regulatory hub comprising at least two DRDs. Monomers, oligomers, and polypeptides optionally include one or more additional components, such as joints, hinges (e.g., detachable and non-detachable hinges), tails (e.g., cytoplasmic tails), and transmembrane domains. As described below in the sections relating to the preparation methods, those skilled in the art can select from various components using the guideposts provided below to achieve the desired outcome (e.g., the location of the oligomerization domain, payload, or DRD relative to the cells in which they are expressed, whether the payload is secreted from the cell or tethered to the membrane; or the desired activity of one or more payloads).
[0136] Regulatory Center
[0137] Typically, a regulatory hub is a polypeptide designed to promote the regulation of a characteristic (e.g., abundance or activity) of a target payload to which the regulatory hub is operably linked and to which the basic building block is a DRD. A regulatory hub according to the present disclosure comprises at least two DRDs, and in some embodiments, such a hub may be formed following oligomerization of at least two polypeptide monomers as described herein. Thus, in some embodiments, at least two DRDs are linked together via a non-covalent bond formed by oligomerization, optionally linked together by an oligomerization domain associated with each DRD, such as Fig.15 In some embodiments, the at least two DRDs are optionally linked via a covalent bond via a linker, such as Fig.15 F and Fig.16 shown.
[0138] DRD
[0139] The DRD interacts with the ligand such that when the DRD is operably linked to a payload, the DRD confers ligand-dependent reversible modulation of a characteristic (e.g., activity) of the payload. Although referred to as a drug-responsive domain, the ligand to which the DRD responds is not necessarily a drug. Suitable DRDs (and their paired ligands), which may be referred to as destabilizing domains or ligand-binding domains, are also known in the art. See, e.g., U.S. Patent Nos. 9,487,787 and 10,137,180, U.S. Publication Nos. 2019 / 0192691; 2020 / 0101142; 2020 / 0172879; 2021 / 0069248 and U.S. Patent Application Nos. 17,251,635; and 17 / 288,373, and WO2018 / 161000; WO2018 / 231759; WO2019 / 241315; US8,173,792; US8,530,636; WO2018 / 237323; WO2017 / 181119; US2017 / 0114346; US2019 / 0300864; WO2017 / 156238; Miyazaki et al., J. Am Chem Soc, 134:3942 (2012); Banaszynski et al. (2006) Cell 126:995-1004; Stankunas, K. et al. (2003) Mol. Cell 12:1615-1624; Banaszynski et al. (2008) Nat. Med. 14:1123-1127; Iwamoto et al. (2010) Chem. Biol. 17:981-988; Armstrong et al. (2007) Nat. Methods 4:1007-1009; Madeira da Silva et al. (2009) Proc. Natl. Acad. Sci. USA 106:7583-7588; Pruett-Miller et al. (2009) PLoS Genet. 5:el000376; and Feng et al. (2015) Elife 4:el0606, the contents of each of which are incorporated herein by reference in their entirety.
[0140] Certain of these and other example DRDs suitable for use with regulatory hubs according to the present disclosure are also provided elsewhere in this specification.
[0141] For example, the DRD can be selected from FKBP (SEQ ID NO: 93), ecDHFR (SEQ ID NO: 18), hDHFR (SEQ ID NO: 37), ER (SEQ ID NO: 96), PDE5 full length (SEQ ID NO: 95), PDE5 ligand binding domain (SEQ ID NO: 94) and CA2 (SEQ ID NO: 1), or a portion of any of the foregoing that maintains DRD function, or an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 1, 18, 37, 93, 94, 95 or 96, or a DRD functional portion thereof. For example, one or more mutations (including truncations, substitutions, and deletions) in the amino acid sequence of FKBP, ecDHFR, hDHFR, ER, PDE5, and CA2 may be beneficial to further destabilize DRD.
[0142] Many DRDs are described herein, but one skilled in the art can identify additional DRDs suitable for use with regulatory hubs and suitable for use in adjustable compositions according to the present disclosure. For example, library screening and structure-guided engineering can be used to identify DRDs to select optimal DRD variants that have sufficient instability in the absence of ligands and sufficient stability in the presence of ligands. By transducing cells (e.g., Jurkat cells) with mutant DRD candidates, random mutagenesis screening can be used to generate variant libraries. In order to generate enriched libraries, cells with desired characteristics (low basal activity / expression and high dynamic range) are selected by testing polypeptide abundance across a range of ligand concentrations. Single cell clones are then generated and characterized to identify candidate DRDs.
[0143] The DRDs described herein are responsive to paired ligands (also referred to as "stabilizing ligands" or simply "ligands"). Optionally, the DRDs are responsive to paired ligands that are small molecule drugs (such as FDA-approved small molecules). However, one skilled in the art can select a DRD and its paired ligand to meet the specific needs of the system. Examples of DRD / ligand pairs are shown in Table 1.
[0144] Table 1. List of DRDs and exemplary ligands
[0145]
[0146] Optionally, the DRD of the present disclosure may be derived from carbonic anhydrase, which is a member of the metalloenzyme superfamily. For example, human carbonic anhydrase (hCA2) may be suitable for use as a DRD. The DRD of the present disclosure may be derived from amino acids 1-260 of CA2 (Uniprot ID: P00918). Optionally, the DRD is derived from CA2 (e.g., amino acids 2-260) comprising amino acids 2-260 of the parent CA2 sequence. This is referred to herein as the CA2M1del mutation (CA2; SEQ ID NO: 5). Optionally, the DRD of the present disclosure comprises a region of human carbonic anhydrase 2 or the entire human carbonic anhydrase 2, and further comprises one or more mutations relative to the full-length sequence selected from M1del, L156H and S56N. Optionally, the DRD is selected from the group consisting of SEQ ID NO: 1, 3, 5, 7 and 9.
[0147] Oligomerization domain
[0148] For the purposes of this disclosure, an oligomerization domain is a sequence that promotes monomers to self-assemble into oligomers, for example, by non-covalent bonding. Such domains can be found in nature, and can be suitable for forming oligomers including payloads and regulatory hubs as described herein. Examples of oligomerization domains include, but are not limited to, phospholamban, collectins, collagen, VASP, CD40L, TNFSF (e.g., TNFSF14, also referred to herein as LIGHT and 4-1BBL), langerin, DAP12, and NKG2C. Optionally, the oligomerization domain is a phospholamban transmembrane domain, collagen 18, avidin, streptavidin, CD40L extracellular domain (ECD), langerinECD, 4-1BBL ECD, VASP tetramer, DAP12, LIGHT extracellular domain (ECD), collectin 7, fungal lectin (5xzk), aspartate transcarbamylase (1EKX), 4-OT trimer, RH3 designed coiled coil (1TGG), HIV-1 gp41, FIV dUTP pyrophosphate, SIV gp41, Ebola virus gp-2, HTLV-1 gp-21 domain, foldon domain, GCN4 domain, T4 fibrin domain, yeast heat shock transcription factor, and human collagen VIII, collagen 18, collagen 15 and hnRNP. Certain oligomerization domains will not oligomerize themselves, and can only oligomerize with different oligomerization domains (such as NKG2C). Such oligomerization domains are referred to herein as hetero-oligomerization domains.
[0149] Fig.15 AE provides non-limiting examples of embodiments of oligomerization domains as described herein. Specifically, in Fig.15 A and Fig.15In the exemplary embodiment of E, the ECD motif of CD40L (SEQ. ID NO. 15) corresponds to the oligomerization domain. Fig.15 In B, the collagen 18 trimerization motif (SEQ.D NO.19) corresponds to the oligomerization domain. Fig.15 In C, the DAP12 dimerization / trimerization motif (SEQ.ID NO.79) corresponds to the oligomerization domain. Fig.15 In D, the collectin 7 trimerization motif (SEQ. ID NO. 23) corresponds to the oligomerization domain. Fig.15 The use of a trimerization motif as an oligomerization domain is illustrated, but any polypeptide motif that promotes self-assembly or association into larger constructs can be used as the basis for an oligomerization domain according to the present disclosure, including a dimerization motif or a motif that causes four or five or six or more polypeptide motifs to assemble together. For example, the VASP motif illustrates an example of a motif suitable for use as an oligomerization domain that will promote self-assembly into a tetramer. As another example, the phospholamban motif is an example of a motif suitable for use as an oligomerization domain that will cause self-assembly into a pentamer regulatory hub.
[0150] Therefore, despite Fig.16 The example regulatory hubs depicted in FIG. 1 all include three DRDs, but a regulatory hub according to the present disclosure may include two or more, three or more, four or more, five or more, six or more, etc. DRDs. Further, the DRDs forming the regulatory hub may be the same or different. Thus, for example, in Fig.15 In F, DRD1, DRD2 and DRD3 may each be the same DRD, or each of DRD1, DRD2 and DRD3 may be a different DRD, or two of the DRDs (eg, DRD1 and DRD2) may be the same DRD, while DRD3 may be a different DRD. Fig.17 A schematic construct of a monomer (top) with a payload, hinge, transmembrane region, cytoplasmic tail, oligomerization domain, and the oligomers produced by self-assembly of the monomer is shown. Any DRD can be used to form a regulatory hub, and certain non-limiting examples of suitable DRDs are mentioned throughout this application (including in patents and applications cited in this specification).
[0151] Payload
[0152] For example, the payload can be any polypeptide with a desired biological function. Such payloads can be modified polypeptides (such as glycosylated polypeptides or lipopeptides) modified by constitutive enzyme activity or by overexpression of a selected enzyme in a cell after expression. The payload includes multiple types of therapeutically important polypeptides or any active parts thereof. For example, the payload includes type I / II membrane proteins such as CD40L, 4-1BBL and CAR or their active parts. The payload also includes cytokines such as IL15, IL12, IL1β, IL2, IL7, IL18, IL21, IL23, IL36, TNFα, IFNγ, IFNα, IFNβ, etc., including their membrane tethered forms or their active parts. The payload also includes intracellular polypeptides such as dnSHP2, T7, RNA polymerase, Cas9 or their active parts. The payload includes secretory proteins such as VEGF-trap and natural cytokines or their active parts. And the payload also includes transcription factors, such as Foxp3, c-Myc, STAT5 and c-Jun, or its active part, or its constitutive active form.Other examples of suitable payloads include cytokine receptors, T-cell receptors (TCR), chimeric antigen receptors (CAR), immunoregulatory proteins other than the immunoregulatory proteins already exemplified, or any active part thereof.In addition to those exemplified above, the payload can also be a gene editing polypeptide or a transcription factor.The payload can also be a combination of polypeptides or their active parts having a desired combination of effects.
[0153] In some embodiments, the effective load is a therapeutic agent selected from cancer therapeutic agents, autoimmune disease therapeutic agents, immunotherapeutics, anti-inflammatory agents, anti-pathogenic agents, gene therapy agents, or combinations thereof. Immunotherapeutics can be antibodies or fragments thereof and variants, TCRs, CARs, chimeric switch receptors, antagonists of co-inhibitory molecules, agonists of co-stimulatory molecules, cytokines, mutant forms of cytokines with altered receptor binding properties (also referred to as mutant proteins), cytokine receptors, chemokines, chemokine receptors, metabolic factors, coagulation factors, enzymes, homing receptors, kinases, phosphatases, dominant negative forms of phosphatases (such as SHP-1 or SHP-2), dominant negative signaling molecules or receptors (such as dominant negative Fas receptors), dominant negative transcription factors, and safety switches.
[0154] In some embodiments, the effective load of the present disclosure can be a cytokine and its fragments, variants, analogs and derivatives, including but not limited to interleukins, tumor necrosis factor (TNF), interferon (IFN), TGFβ and chemokines. Interleukins can be selected from IL15, IL12, IL1β, IL2, IL7, IL18, IL21, IL23, IL36 and variants thereof, including membrane-bound polypeptides, secreted polypeptides, fusion polypeptides, or cytokine mutants (also called mutant proteins) with altered receptor binding properties and bicistronic forms of interleukins, and combinations thereof.
[0155] For example, IL12 can include p35 and p40 subunits encoded by a single nucleic acid that produces a single-chain polypeptide. The single-chain polypeptide can be produced by placing the p35 subunit at the N-terminus or C-terminus of the single-chain polypeptide. Similarly, the p40 subunit can be located at the N-terminus or C-terminus of the single-chain polypeptide. As another example, the useful load can be a bicistronic IL12 containing p40 and p35 subunits.
[0156] In some embodiments, the payload can be an active portion or variant of a polypeptide having a desired biological function, as long as the payload retains the desired biological function. For example, the payload can be a p40 subunit of IL12 or a p35 subunit of IL12 or a variant of IL12 that promotes NK cell survival, regulates NK cell and T cell activation and proliferation, and / or supports NK cell development from hematopoietic stem cells.
[0157] In some embodiments, the payload of the present disclosure can be a chimeric antigen receptor (CAR) comprising an extracellular targeting domain (e.g., a scFv that recognizes a specific tumor antigen or other tumor cell surface molecule), a transmembrane domain / region, and an intracellular signaling / activation domain (e.g., the signaling region of CD3ζ, and / or one or more co-stimulatory signaling domains, such as the co-stimulatory signaling domains from CD28, 4-1BB (CD137), and OX-40 (CD134)).
[0158] In some embodiments, a payload that reduces the immune response in a subject can be selected. For example, the payload can be an anti-cytokine, such as a neutralizing antibody to tumor necrosis factor (TNF)-αH or an interleukin. In some embodiments, the payload of the present disclosure targets B cell depletion, such as a neutralizing antibody to CD20, CD22, CD28, CTLA-4, and B lymphocyte stimulator (BLyS).
[0159] In some embodiments, the payload can also be contractile proteins (e.g., actin and myosin), enzymes (e.g., lactase and pepsin), hormones (e.g., insulin, oxytocin, and growth hormone), structural proteins (e.g., keratin, collagen, and elastin), storage proteins (e.g., ovalbumin and ferritin), transport proteins (e.g., hemoglobin), membrane-bound proteins (e.g., class I, II, or III transmembrane proteins; receptors, transport proteins, etc.).
[0160] In some embodiments, the payload of the present disclosure can be one or more components of a gene editing system. In such embodiments, oligomers or engineered regulatable polypeptides regulate the activity of a gene editing system, and thus regulate the expression of a downstream target protein. As used herein, a target protein refers to a protein selected for gene editing, including, for example, a protein having a genetic mutation that causes a deleterious effect in a subject or in a cell. For example, the payload of the present disclosure can be a Cas protein (CRISPR-associated protein), including Cas9 and Cas12. The Cas protein can be changed or otherwise modified. For example, the Cas protein can be a dead Cas9 (deadCas9). Optionally, the Cas9 protein is an enzymatically active Cas9 protein, a Cas9 protein wild-type protein, a Cas9 protein nickase, or a nuclease-invalid or nuclease-deficient Cas9 protein. Such payloads optionally include nucleases (e.g., zinc finger nucleases, TALEN (nucleases based on transcription activator-like effectors) or meganucleases) and / or recombinases, such as Cre recombinases.
[0161] Payloads useful in the present disclosure also include polypeptides involved in nucleic acid synthesis and replication, such as DNA and RNA polymerases, transcription factors, primases, helicases, RNases, ligases, topoisomerases, endonucleases, IRES, and telomerases.
[0162] Connectors
[0163] Linker sequences (linkers) are known in the art and are described in the references cited herein. Linkers include, for example, GS linkers, GSG linkers, and GGSG (SEQ ID NO: 239) linkers. These linkers are one or more repeats of a subunit. Thus, a GS linker is a GS n linker (SEQ ID NO: 240), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more. Similarly, the GSG linker is GSG nlinker (SEQ ID NO: 241), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more. The GGSG linker (SEQ ID NO: 239) is a GGSGn linker (SEQ ID NO: 242), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more.
[0164] Hinge and transmembrane domains
[0165] Hinge sequence is a short sequence of amino acids that promotes flexibility between connected components. Hinge sequence can be any suitable sequence derived from or obtained from any suitable molecule. Hinge sequence can be derived from all or part of immunoglobulin (e.g., IgG1, IgG2, IgG3, IgG4) hinge region, i.e., a sequence (e.g., IgG4Fc hinge) that falls between the CH1 and CH2 domains of immunoglobulin, or the extracellular region of type 1 membrane protein (such as CD8αCD4, CD28 and CD7), the extracellular region can be a wild-type sequence or its derivatives. Some hinge regions include immunoglobulin CH3 domains, or both CH3 domains and CH2 domains. In some embodiments, hinge is derived from a transmembrane domain.
[0166] The transmembrane domains useful in the engineered regulatable polypeptide constructs of the present disclosure may include, for example, an MHCl transmembrane domain, a CD8α transmembrane domain, a B7-1 transmembrane domain, a CD4 transmembrane domain, a CD28 transmembrane domain, a CTLA-4 transmembrane domain, a PD-1 transmembrane domain, or a human IgG4 Fc region.
[0167] Intracellular / cytoplasmic or transmembrane tail
[0168] Optionally, monomer or polypeptide construct provided herein comprises intracellular / cytoplasm or transmembrane tail.Optionally, intracellular / cytoplasm or transmembrane tail is CD8, CD40L, LIGHT, NKG2C or B7.1 intracellular tail.The disappearance of transmembrane region in construct can be designed for example for secretory payload or payload with intracellular or intranuclear activity.
[0169] Label
[0170] Optionally, monomers or polypeptides described herein include tags. Such tags allow separation or detection of monomers or polypeptides or separation or detection of effective loads. Such tags optionally include fluorescent proteins (e.g., green fluorescent protein), His-tags, HA-tags, Myc tags, FLAG tags, mCherry, CD20, CD34, nerve growth factor receptor (NGFR), truncated NGFR (tNGRR), epidermal growth factor (EGFR) or truncated EGFR (tEGFR).
[0171] Ligand
[0172] The ligand can be any agent that binds to the DRD of the regulatory center of the engineered adjustable polypeptide or oligomer described herein, and the effective amount of the agent causes a measurable change in the modification of the characteristics (e.g., abundance, availability, activity) of the payload operably connected to the DRD. In some embodiments, the ligand can be a synthetic molecule. In some embodiments, the stabilizing ligand of the present disclosure can be a small molecule compound. The stabilizing ligand is optionally a small molecule therapeutic drug previously approved by an administrative agency such as the U.S. Food and Drug Administration (FDA). Examples of stabilizing ligands suitable for the regulatory center described herein and their corresponding DRDs are shown in Table 1, shown in the sections citing suitable DRDs in the patents and applications cited above, and shown in U.S. Patent No. 9,487,787 filed on March 33, 2012, U.S. Patent No. 10,137,180 filed on September 6, 2013, PCT Application No. PCT / US2018 / 037005 filed on June 12, 2018, 2019 The disclosures of PCT application Nos. PCT / US2019 / 036654, filed on June 12, 2019, PCT application No. PCT / US2019 / 057698, filed on October 23, 2019, PCT application No. PCT / US2020 / 021596, filed on March 6, 2020, and U.S. application No. 16 / 558,224, filed on September 2, 2019, are incorporated herein by reference in their entirety.
[0173] Nucleic acids, vectors and cells
[0174] Provided herein is an expressible nucleic acid construct encoding one or more engineered adjustable polypeptide monomers or adjustable polypeptides as described herein. In an embodiment, the nucleic acid construct encoding a monomer includes an oligomerization domain and at least one DRD and / or at least one useful load, and optionally includes additional components, such as hinges, joints, transmembrane domains, tags, and intracellular / cytoplasmic and transmembrane tails as described herein. In certain embodiments, a single nucleic acid construct includes a nucleic acid sequence encoding all components of a monomer as described herein. For example, the nucleic acid construct encodes at least a useful load, a DRD, and an oligomerization domain. When expressed multiple times, the monomer can be assembled into oligomers, such as dimers, trimers, tetramers, pentamers, or hexamers according to the oligomerization domain and by the oligomerization domain. Optionally, a single nucleic acid construct encodes multiple copies of the same or different monomers, which are assembled into oligomers when expressed. Optionally, certain nucleic acid constructs encode an oligomerization domain and at least one payload, and certain nucleic acid constructs encode an oligomerization domain and at least one DRD, such that when expressed they assemble into an oligomer comprising at least one payload and at least two DRDs.
[0175] In an embodiment, the nucleic acid construct encoding the regulatable polypeptide includes at least one payload and at least one regulatory hub comprising at least two DRDs. The nucleic acid construct encoding the regulatable polypeptide may include additional components, such as hinges, linkers, transmembrane domains, tags, and intracellular / cytoplasmic and transmembrane tails as described herein.
[0176] The nucleic acid constructs encoding monomers and regulatable polypeptides optionally also encode additional components, such as signal sequences and cleavage sites including shedding domains. The constructs optionally also comprise promoter sequences and other regulatory elements (enhancers, translation control elements (e.g., IRES) and elements controlling half-life).
[0177] Further provided are numerous nucleic acid constructs, each construct encoding one or more monomers or polypeptides as described herein. Such numerous constructs optionally provide oligomeric monomers after expression. The numerous constructs can be the same or different. Therefore, the numerous nucleic acids can encode the same polypeptide or monomer, or can encode polypeptides or monomers comprising different DRDs, payloads and / or additional components.
[0178] Also provided herein is a vector for expressing one or more nucleic acids in the nucleic acid. Such vectors can be selected from viral vectors and non-viral vectors, plasmids, cosmids and artificial chromosomes. For example, the vector can be a viral vector, such as a lentiviral vector, a retroviral vector, an adenoviral vector or an adeno-associated viral vector. The vector optionally comprises a nucleic acid sequence encoding a transposase and / or a nuclease. Examples of non-viral vectors include physical vectors (such as electroporation) and chemical vectors (such as lipid nanoparticles).
[0179] A cell containing one or more nucleic acid constructs or vectors as described herein is provided. The cell provides an expression system or a therapeutic target for a monomer, oligomer or polypeptide as described herein. Suitable cells include immune cells or stem cells. Optionally, the immune cell is a primary human T cell collected after stimulation with G-CSF, bone marrow or cord blood, such as a T cell derived from human peripheral blood mononuclear cells (PBMC) PBMC. In an embodiment, the immune cell is a tumor infiltrating lymphocyte (TIL) collected, for example, from a tumor. The immune effector cell can also be a NK cell, an αβT cell, an iNKT cell, a γδT cell, a macrophage, a B cell, a dendritic cell, a myeloid-derived progenitor cell, an eosinophil, a basophil, a neutrophil or a Treg. Optionally, the stem cell is a hematopoietic stem cell, a human embryonic stem cell or an iPSC. The cell provided herein is optionally a mammalian cell, or more specifically a human cell.
[0180] Preparation method
[0181] The present disclosure provides methods for preparing nucleic acid constructs and vectors encoding monomers and polypeptides of the present disclosure, methods for preparing monomers and polypeptides of the present disclosure by expression of nucleic acid constructs, and methods for preparing cells comprising the nucleic acid constructs or vectors described herein.
[0182] Fig.18Provided are embodiments of the process of designing nucleic acid constructs and vectors encoding monomers or polypeptides of the present invention and subsequently delivering the constructs or vectors for expression in cells. As shown, DRD / ligand pairs are selected to regulate the desired payload. Optionally, DRDs with ligand pairs as FDA-approved small molecule drugs are selected. In some embodiments, the small molecule drug combination approved by DRD / FDA is selected to make it clinically tractable (e.g., the ligand can regulate the abundance of the payload or regulate the activity of the payload within the approved FDA dosage range of the ligand). Then, nucleic acids or vectors are designed to encode the building blocks / components of polypeptides or monomers as described herein, which include at least one payload and two selected DRDs in the case of polypeptides, and include at least one oligomerization domain and at least one selected DRD, or at least one payload, or at least one payload and at least one selected DRD in the case of monomers. Nucleic acids or vectors can be further designed to encode additional building blocks / components, such as transmembrane domains, joints, hinges, and tags. Using the present disclosure, those skilled in the art can select appropriate components and sort them in the construct to achieve the desired outcome. For example, the order of the building blocks affects whether DRD regulates the N-terminal or C-terminal payload.
[0183] As another example, linkers and linker lengths can affect "constitutive" activity levels (i.e., basal activity in the absence of ligand), and in embodiments, specific linkers and lengths are selected to maximize the on-state (e.g., maximum activity level) while maintaining low basal activity levels and ligand (e.g., drug) responsiveness. As yet another example, a specific hinge can allow conformational changes and thereby affect ligand responsiveness, and is therefore selected to produce a sufficient dynamic range to obtain a desired range of payload abundance and biological activity (i.e., an acceptable range of payload activity corresponding to a change in ligand from zero or minimal saturation to maximum saturation). For example, if Fig.19 As shown, if the goal is to create a membrane-tethered cytokine with sufficient dynamic range, such as IL15, the polypeptide optionally includes a payload (IL15), a linker, a hinge, a transmembrane region, a tail, and a DRD from the N-terminus.
[0184] In some embodiments, the nucleic acid sequence encoding the polypeptide or monomer can be engineered to include one or more additional components so that when expressed in a cell, the payload is localized inside the cell membrane (optionally, tethered to the membrane or released into the cytoplasm), and in certain embodiments, localized outside the cell membrane (optionally, tethered to the membrane or released outside the cytoplasm (i.e., shed from the membrane or cleaved). Similarly, the nucleic acid construct is optionally configured to encode a polypeptide monomer that oligomerizes through the association of an intracellular, transmembrane, or extracellular oligomerization domain. Thus, all or a portion of a regulatory hub or oligomerization domain can be engineered to reside inside a cell, inside a cell membrane, or on the surface of a cell (e.g., tethered to the cell surface).
[0185] See also Fig.15 .
[0186] In some embodiments, a nucleic acid sequence encoding a polypeptide monomer construct or an regulatable payload composition can be engineered to include one or more of these additional components such that when expressed in a cell, the regulatable payload composition is engineered to have a signal sequence to transport part or all of the engineered regulatable polypeptide construct into the secretory pathway.
[0187] After designing the construct for proper function (including localization), appropriate components (such as promoters, enhancers, polycistronic expression, translation control and half-life control elements) are selected to achieve the desired control of the abundance or activity of the effective load. In addition, nucleic acid constructs are designed for cistron or polycistronic expression as required for the desired expression of the various engineered components.
[0188] In addition, vehicle / vector is selected and designed to deliver nucleic acid construct into desired cell.For example, vehicle can be selected from those described previously, including viral vector (such as lentiviral vector, retroviral vector and adeno-associated vector), plasmid, cosmid and artificial chromosome.Such vector can be designed to encode transposase, nuclease and control translation element (for example, IRES).The selection of carrier may also affect the selection of various building block components.For example, the carrier of smaller construct may need to use smaller DRD.
[0189] Cells for engineering can be separated from any biological sample, including, for example, blood (e.g., cord blood or peripheral blood), bone marrow, fetal tissue (human embryonic stem cells) or tumors. Before transduction with described nucleic acid and vector, cells can be modified cells, such as modified to pluripotent stem cells (e.g., induced pluripotent stem cells (iPSC)) or CAR T cells.
[0190] For example, isolated T cells or tumor infiltrating lymphocytes (TIL) can be isolated from a biological sample, transduced, and optionally expanded in culture. Such expansion can be carried out, for example, by contacting the transduced cells with IL2, feeder cells, recombinant antigens, or antibodies that stimulate cell expansion.
[0191] The cells to which the nucleic acid is delivered are selected based at least in part on the ability of the cells to allow the polypeptide or monomer disclosed herein to be expressed and to allow the payload activity to be within a sufficient dynamic range. Optionally, in the absence of the nucleic acid or vector provided, the cells express little or no payload. In certain embodiments, those skilled in the art will select cells that need to increase the payload activity or abundance in cells expressing the payload. In certain embodiments, those skilled in the art will select cells that need gene editing. In certain embodiments, the cells are selected as effector cells, such as immune effector cells.
[0192] A person of ordinary skill in the art who applies the knowledge of the present disclosure can construct a variety of monomers, polypeptides and oligomers within the scope of the present disclosure, as well as nucleic acids and vectors encoding them, without being limited to those explicitly exemplified herein. For example, as described, regulatory hubs, payloads, DRDs, oligomerization domains, and additional components (such as joints, tails, transmembrane domains, signal sequences, hinges, etc.) can be selected to create various polypeptides, oligomers, and nucleic acids encoding them after considering such factors as the following: the desired therapeutic outcome, whether the payload is membrane-bound or secreted, whether the payload acts intracellularly or extracellularly, and whether the oligomerization domain should be located intracellularly, extracellularly, or transmembraneally. Therefore, the exemplary embodiments are non-limiting and are useful for providing guidance to those skilled in the art to implement other embodiments within the scope of the present disclosure.
[0193] How to use
[0194] Disclosed herein are methods for modulating payload function, such as methods for modulating the abundance, availability, and / or activity ("activity") of a payload. In some embodiments, the modulation method is a method for modifying the activity of a payload, comprising engineering a cell to express a payload operably linked to a regulatory hub comprising two or more DRDs responsive to a ligand. In some such embodiments, the activity of the payload (e.g., corresponding to the abundance and / or availability of the payload) is reduced compared to the activity of the payload in a control cell (e.g., a cell engineered to express the payload independently of the DRDs).
[0195] Optionally, the effective load has a biological activity level within the range of maximum activity from the basal activity level in the absence of a ligand to the presence of a saturating amount of a ligand, and the method is a method for regulating the activity of the effective load, the method comprising contacting a cell engineered to express an effective load operably connected to a regulatory hub with an effective amount of a ligand so that the activity of the effective load is increased relative to the basal activity level. In some embodiments, the method comprises contacting the cell with a selected amount of a ligand, wherein the selected amount of a ligand results in a selected activity level of the effective load. In certain embodiments, the method comprises alternatively contacting the cell with different selected amounts of a ligand to achieve different selected activity levels within the range from a basal level to a maximum level.
[0196] The contact step can be performed in vitro, in vitro or in vitro. The contact step is optionally performed to achieve a continuous selected activity of the payload (i.e., to achieve a continuous on-state of the payload) or to achieve an intermittent activity of the payload (i.e., to provide a pulsed delivery of the payload between the on-state and the off-state). "Off-state" means that the payload activity is a basal activity level. "On-state" means a selected activity level in the presence of an effective amount of ligand, which is greater than the off-state. The continuous activity of the payload can be achieved by continuous contact of the DRD with an effective amount of ligand or by providing one or more subsequent contact steps of the DRD with the ligand, wherein the one or more subsequent contact steps are performed before the activity level of the payload from the previous contact step reaches the basal activity level. Each contact step can be varied according to the amount of the ligand, so that when more ligands are used, more payload activity is generated, and when less ligands are used, less payload activity is generated. Therefore, the amount of the ligand can vary with the subsequent contact step to increase or decrease the amount and / or activity of the payload over time. In order to achieve the desired activity level pattern, each contact step can also vary relative to frequency. Because the regulatory hubs described herein result in a lower off-state and optionally a wider dynamic range of activity for the payload compared to the same payload in a control construct, the activity of the payload can be modulated from a lower off-state and optionally varied over a larger range compared to the payload in a control construct.
[0197] Also disclosed is a method of delivering a payload to a subject, such as delivering a therapeutically effective payload to a subject in need, thereby administering a nucleic acid construct or a vector as described herein to a subject. The method results in, for example, expressing one or more polypeptides or monomers in a target cell of a subject, which self-assemble to form an oligomer as described herein. The method may also include controlling the dosage or duration of administering a payload to a subject. For example, the method optionally also includes administering a selected amount of paired ligands to a subject to deliver a selected activity of a payload to the subject. The ligand may be delivered to achieve continuous or intermittent payload activity in a subject. Continuous payload activity may be a substantially consistent activity level, or the activity level may be regulated. Intermittent activity between the off state and the on state includes regulating activity between the off state and the substantially consistent on state, or between the off state and the varying on state activity level. When more activity of the payload is needed, a higher dose of ligand is administered or a longer duration of ligand administration is implemented, and when less activity is needed, the ligand dosage is selected to be reduced or eliminated. The dosage and duration of ligand administration and the resulting activity of the payload may be selected to avoid unacceptable or undesirable side effects or toxicity in a subject. The dosage of ligand and the schedule for applying ligand dosage can be determined empirically by those skilled in the art based on the amount of the obtained effective load, the activity of the effective load or one or more signs of the influence of the effective load activity. The scope of application of ligand is any amount from zero or more to saturation dose, and the scope of the effective load activity obtained is from the basic level to the maximum level, optionally with such sufficient dynamic range, which allows the required dose response of ligand and the accompanying activity range of effective load (for example, for a given ligand and effective load, the difference range of the disconnected state and the maximum effective load activity will be produced by at least 10 times of the scope of the ligand). This sufficient dynamic range enables fine-tuning, and makes the dose response curve not too steep to be unacceptable. In embodiments, the dosage or frequency of ligand administration and the abundance and activity of the effective load obtained are selected to avoid, alleviate or limit unacceptable or undesirable adverse side effects, and will vary with the age, illness and / or sex of the subject and the type of the illness treated, the degree of illness or other therapeutic agents whether included in the treatment regimen. The appropriate dosage for the ligand of a given category can be found in the guide in the literature.
[0198] As a further example, for a subject with cancer, a nucleic acid construct or vector according to the present disclosure is provided to the subject, wherein the nucleic acid construct or vector encodes a payload operably connected to a regulatory hub, and wherein the payload targets a tumor cell or an immune cell, which in turn targets the tumor cell. This method optionally includes administering to the subject a nucleic acid construct or vector according to the present disclosure, wherein the nucleic acid construct or vector encodes a payload operably connected to a regulatory hub, wherein the payload is an immune checkpoint inhibitor, a cytokine, a CAR or a TCR.
[0199] Also provided herein is a method for delivering a payload operably connected to a regulatory center to a subject by administering to the subject a cell containing nucleic acid or a vector as described herein. Such a method may also include separating cells from a subject, transducing separated cells with nucleic acid or a vector encoding a monomer described in the disclosure (which is assembled into an adjustable oligomer when expressed) or an adjustable polypeptide, amplifying the cell in vitro, and providing the cell to the same or different subject. Payload is selected to treat a subject receiving the cell. The subject may suffer from cancer, autoimmune diseases, gene mutations, essential polypeptide deficiency, etc. For example, the transduced cell may be an immune effector cell (e.g., NK cells, iNKT, αβT cells, γδT cells, tumor infiltrating lymphocytes (TIL), macrophages, B cells) or stem cells). The cell may be separated from the same subject (autologous source) receiving the transduced cell, or the cell may be separated from different subjects (e.g., allogeneic sources). For example, when a subject has cancer, T cells or TILs can be isolated from the subject and engineered to express cytokines, CARs, and / or TCRs. For example, the cell can be a CD19 CAR-T cell. The cell is optionally expanded and the cell or expanded cell population is administered to the same or different subject. In certain embodiments, T cells, CAR-T cells, NK cells, or TILs are injected at a rate of about 1000 cells / injection to a maximum of about 10 billion cells / injection (such as 1×10 10 , 1×10 9 , 1×10 8 , 1×10 7 , 5×10 7 , 1×10 6 , 5×10 6 , 1×10 5 , 5×10 5 , 1×10 4 , 5×10 4 , 1×10 3 , 5×10 3cells / injection, or any range between any two of these numbers, including the endpoints). Optionally, 1×10 8 Up to 1×10 10 Optionally, the cells are administered once, twice, three times, or four times as needed.
[0200] In the treatment method, the ligand dosing regimen (including the selected amount of the ligand for administration to the subject and the frequency of administering the selected amount of the ligand) is selected to result in the regulation of the payload and / or the desired outcome of the subject. The outcome of the subject is optionally monitored. Thus, for example, the number of malignant cells in the sample, the circulating tumor DNA in the sample, or the size of the solid tumor during imaging can be detected. If the desired endpoint is reached (e.g., showing successful treatment of cancer), the ligand can be reduced or deactivated to reduce or eliminate the payload, such as reducing the abundance, availability and / or activity of the payload to below a predetermined threshold, thereby eliminating or mitigating unwanted or undesirable side effects. Similarly, if the subject suffers from a cytokine storm, an allergic reaction or other adverse effects due to the payload, the ligand can be reduced or deactivated. Also disclosed herein is a method for regulating the expression of a downstream target protein of a gene editing process. In some embodiments, such a method includes engineering the cell to express an oligomer or an engineered regulatable polypeptide, the oligomer or the engineered regulatable polypeptide comprising a payload operably linked to a regulatory hub, such as a CAS9 protein or a transcription factor protein. In certain embodiments, for subjects with genetic mutations, a nucleic acid construct or vector according to the present disclosure is provided to deliver a nucleic acid editing polypeptide or system that is operably connected to a regulatory hub. Target cells in a subject are transduced with a nucleic acid construct or vector to allow the gene editing payload to modify the nucleic acid (e.g., genomic DNA or RNA) of the transduced cells. The activity level of the payload and therefore the expression of the target protein can be regulated by administering a ligand to the subject. Systems for nucleic acid editing are known in the art, such as CRISPR / Cas 9 systems, TALEN, retrotransposons, etc. Nucleic acid constructs or vectors can be engineered to encode one or more components of any system in the system so that one or more nucleic acids in the transduced cells of the subject are edited to provide the desired nucleic acid modification.
[0201] definition
[0202] The terms "about" and "approximately" when used to refer to a measurable value such as an amount, concentration, dose, time, temperature, activity, level, number, frequency, percentage, dimension, size, weight, location, length, etc., are meant to take into account variations due to experimental error, which may encompass variations of ±15%, ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of the specified amount, concentration, dose, time, temperature, activity, level, number, frequency, percentage, dimension, size, weight, location, length, etc. All measurements or values are implicitly understood to be modified by the word about, even if the measurement or value is not expressly modified by the word about. In cases where the terms "about" and "approximately" are used in conjunction with the location or position of a region within a reference polypeptide, these terms encompass variations of ± up to 20 amino acid residues, ± up to 15 amino acid residues, ± up to 10 amino acid residues, ± up to 5 amino acid residues, ± up to 4 amino acid residues, ± up to 3 amino acid residues, ± up to 2 amino acid residues, or even ± 1 amino acid residue.
[0203] Reference is made herein to a "basal level of activity". As used herein, a basal level can be zero, near zero, or any amount in the absence of an exogenous ligand. Basal activity can occur due to endogenous levels of the same or a different ligand, or can occur due to resting levels produced by the payload in the absence of an exogenous ligand.
[0204] References to "biological activity" should be understood to mean under appropriate conditions, even if not so stated. As used herein, "contacting" should be understood to mean providing an agent (such as a ligand) to a target (such as a DRD) so that the agent and the target can contact each other. For example, contacting includes providing a ligand to a cell in vitro (e.g., when the DRD is located outside the cell or on the surface of the cell). As another example, contacting also includes providing a ligand to a cell, wherein the DRD is located inside the cell, so that the ligand reaches the cytoplasm. Similarly, cells can be contacted in vivo by administering a ligand to a subject so that the ligand reaches the cell or DRD.
[0205] As used herein, the term "control construct" refers to a construct similar to a tested engineered regulatable oligomer or engineered regulatable polypeptide ("test construct"), except that the control construct lacks an oligomerization domain and has only a single DRD.
[0206] "DRD" should be understood to mean a ligand-responsive domain, even if not so specified.
[0207] A "heterologous oligomerization domain" as described herein is a first oligomerization domain on a first monomer that promotes oligomerization by a second oligomerization domain on a second monomer, wherein the second oligomerization domain is different from the first oligomerization domain and wherein the first oligomerization domain does not promote oligomerization with the same oligomerization domain.
[0208] The terms "ligand," "pairing ligand," and "stabilizing ligand" are used interchangeably and mean the same thing when used with respect to a drug response domain ("DRD") and / or a regulatory hub.
[0209] As used herein, "operably linked" means that in the presence of a paired ligand, a regulatory hub or DRD is directly or indirectly connected to a payload to change a measurable feature of the payload (e.g., changing the activity level of the payload compared to the activity level in the absence of a paired ligand). In some embodiments, the amount of payload measured in the presence of an effective amount of a ligand and / or the level of activity are increased compared to the level of expression or activity measured in the absence of a ligand. The effective amount of a ligand means the amount of ligand required to observe an increase in the measured value of the amount or activity of the payload. In some embodiments, the effective amount will not be so large as to produce unacceptable toxicity or off-target effects. Optionally, the measurable feature is a treatment outcome, the amount of payload in a sample, or the level of biological activity of the payload (measuring the amount of the payload can be used as a surrogate for the level of biological activity).
[0210] The term "payload" refers to an agent whose abundance, activity, availability, expression, function or other characteristic is modulated by a DRD and / or a regulatory center.
[0211] Where the phrase "connected" or "bound to" etc. is used, the phrase "directly or indirectly" should be understood to follow unless otherwise clearly indicated or illogical in the context. Thus, the phrase "a DRD connected to another DRD" or "two connected DRDs" in both cases means that a first DRD is directly or indirectly connected to a second DRD. For example, "two connected DRDs" etc. encompass situations where two DRDs are not directly connected to each other but are associated with each other because each DRD is connected to an oligomerization domain and the respective oligomerization domains are connected, for example, via a non-covalent bond.
[0212] The details of one or more embodiments of the present disclosure are set forth in the specification and the accompanying drawings. It should be understood that other embodiments may be utilized and that structural or method changes may be made without departing from the scope of the present disclosure. In other words, illustrative embodiments and aspects are described below. However, it should be understood that in the development of any such actual embodiments, many implementation-specific decisions may be made to achieve the developer's specific goals, such as complying with system-related and business-related constraints, which will vary from implementation to implementation. In addition, it should be understood that such development efforts may be complex and time-consuming, but will still be a routine task for those of ordinary skill in the art who benefit from the present disclosure.
[0213] Publications cited herein and the materials for which they are cited are hereby expressly incorporated by reference in their entirety.
[0214] The following examples are intended to further illustrate certain aspects of the methods and compositions described herein and are not intended to limit the scope of the claims.
[0215] Example
[0216] Example 1. Cloning of IL12-X and CD19-IL12-X constructs
[0217] IL12-(241-252 and 254-262) and CD19-IL12-(297-316, 319-332) plasmids were constructed in pELNS vector (third generation self-inactivating lentiviral expression vector) using standard molecular biology techniques. Gene fragments (Gblocks or strings DNA) encoding IL12, glycine-serine linkers, various hinges, transmembrane domains and cytoplasmic tails were purchased from Integrated DNA Technologies or Thermo-fisher scientific. The gene fragment was inserted into the pELNS vector and the gene fragment was placed under the control of the EF1a promoter using Gibson assembly (NEBuilder Hifi). The assembled plasmid was transformed into Escherichia coli (NEB stable) for amplification and the sequence was confirmed before continuing with virus production.
[0218] Example 2. Regulation of IL12 from tandem IL12 mCherry constructs in HEK cells
[0219] HEK-293 and T cells were cultured in standard medium (DMEM (Fisher Scientific catalog number 11-960-044) with 10% FBS (Fisher Scientific catalog number 10-082-147) and 1% P / S (ThermoFisher catalog number 15140122). Lipofectamine HEK293 and T cells were transiently transfected with 2000 and 1 μg of plasmid DNA for each of the following: IL12-223, 241, 243, 244, 245, 247, 248, 249, 250, 251, 254, 255, 256, 258, and 260. 100 μM acetazolamide was added one day after transfection, and the cells were cultured for another day. mCherry was used as a transfection marker, and anti-IL12p40 / 70-V450 catalog number 561380BD was used for IL12 staining. Figure 5A , Figure 5B and Figure 5C The flow cytometry graphs in show the surface abundance of IL12 in HEK cells in the presence or absence of ACZ. IL12-223, which was configured without an oligomerization motif, showed a higher basal payload abundance on the cell surface compared to constructs IL12-241, 245, 254, 256, 258, and 260, which were configured with a trimerization motif.
[0220] Example 3. Regulation of IL12 from tandem IL12 mCherry constructs in Jurkat cells
[0221] Jurkat, clone E6-1, cells were cultured in standard culture medium (RPMI + GlutaMAX supplement: Life Technologies catalog number 61870127, fetal bovine serum (FBS) Life Technologies catalog number 10-082-147). Jurkat cells were transduced with lentivirus produced from each of IL12-217, IL12-241, IL12-243, IL12-245, IL12-247, IL12-248, IL12-254, IL12-256, and IL12-258. The components of these constructs are depicted in Figure 3 Jurkat cells were transduced to 10%-25% positive as determined by using mCherry as a transduction marker. Five days after transduction, cells were treated with 100 μM acetazolamide or DMSO and cultured for an additional day. mCherry was used as a transduction marker and anti-IL12p40 / 70-V450 Catalog No. 561380 BD was used for IL12 staining. Figure 6Geometric MFI indicating IL12 construct expression on mCherry positive Jurkat cells in the presence and absence of ACZ is shown. Note that cells transduced with trimerization constructs (IL12-245, 247, 248, 254, 256) have low IL12 expression (off state) in the absence of ACZ. The numbers above the cells treated with ACZ indicate the high fold change between the on and off states. MFI is calculated for cells within the mCherry gate.
[0222] Example 4. Regulation of shed IL12 from tandem IL12 mCherry constructs in primary human T cells
[0223] On day 0, primary human T cells were stimulated with Dynabeads (T-expander CD3 / CD28) at a 3:1 bead:cell ratio in medium containing 10% fetal bovine serum (FBS). The next day, lentivirus generated with constructs (IL12-241, 245, 247, 256, 223, 260 and CD19-IL12-192) and controls were added in the presence of reduced serum (5% FBS). The components of these constructs are depicted in Figure 3 On day 2, cells were diluted 1:2 with fresh 10% FBS medium. On day 5, cells were subjected to mCherry transduction analysis and replated to account for differences in transduction efficiency, the medium was changed, and cells were treated with 100 μM acetazolamide or DMSO. Cytokines that had accumulated for 24 hours in culture supernatants (from 100,000 cells per 200 μL medium) were measured using human IL12p70 (and / or human interferon-γ) MSD V-plex assay kits (Meso Scale Discovery). Figure 7 The levels of IL12p70 secreted from T cells transduced with different constructs are shown. The same constructs tested in Jurkat cells produced similar results in transduced T cells. Note that only IL12s with hinges that define the shedding mechanism will result in an expanded dynamic range of regulation for the shedding IL12 fraction in the cell supernatant.
[0224] Example 5. Regulation of membrane-bound IL12 constructs in primary human T cells
[0225] On day 0, primary human T cells were stimulated with Dynabeads (T-expander CD3 / CD28) at a bead: cell ratio of 3:1 in a medium containing 10% fetal bovine serum (FBS). The next day, lentivirus produced with constructs expressing mCherry and membrane-bound trimerized flexi-IL12 (IL12-241, 245, 247, 256, 260 and CD19-IL12-192) and controls was added in the presence of reduced serum (5% FBS). On day 2, cells were diluted 1:2 with fresh 10% FBS medium. On day 5, cells were subjected to mCherry transduction analysis, the medium was replaced, and the cells were treated with 100 μM acetazolamide or DMSO. Twenty-four hours later, T cells were analyzed by FAC. mCherry was used as a transduction marker, and anti-IL12p40 / 70-V450 catalog number 561380BD was used for IL12 staining. Alternatively, cells were expanded for a total of 10-11 days and then frozen in liquid nitrogen. Next, T cells were thawed and counted. 1-2×10 5 Cells were plated in each well of a 96-well V-bottom plate, restimulated with soluble CD3 / CD28 Immunocult reagent (Stem Cell Technologies), and treated with a dose response of acetazolamide ranging from 0-100 μM. After overnight incubation, transduction efficiency was analyzed by flow cytometry using mCherry. Surface expressed IL12 was detected with an anti-IL12p70 antibody (BD). Figure 8 Geometric MFI of surface IL12p70 expression on mCherry or CAR+ cells is shown. Ligand concentration dose response curves were fitted using Prism software.
[0226] Table 2. Fold changes in surface IL12 abundance following transduction of constructs.
[0227] Constructs Change multiple EC50(μM) IL12-241 5.3 2.6 IL12-245 8.3 4.6 IL12-247 8.8 1.1 IL12-256 5.6 2.4 IL12-260 9.8 6.2 CD19-IL12-192 2.2 2.7
[0228] Example 6. Measurement of membrane-bound IL12 on T cells following construct transduction
[0229] An overview of the test schematic is given in Figure 4On day 0, primary human T cells were stimulated with Dynabeads (T-expander CD3 / CD28) at a bead:cell ratio of 3:1 in medium containing 10% fetal bovine serum (FBS). The next day, any construct from CD19-IL12-192 (SEQ ID NO: 124) and CD19-IL12 (297-316 or 319-332) (SEQ ID NO: 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232) was packaged into lentivirus.
[0230] Table 3. Amino acid and nucleic acid sequence IDs of CA2 variants, IL12, and tested constructs
[0231]
[0232]
[0233]
[0234]
[0235]
[0236]
[0237]
[0238] On day 2, cells were diluted 1:2 with fresh 10% FBS medium. On day 3, cells were amplified 1:3 with fresh medium. On day 6, flow cytometry was used to assess the transduction efficiency of cells. As a readout of cell transduction, CD19-CAR expression was detected using CD19-Fc reagent and then fluorescently labeled anti-human Fc antibody. Dynabeads were removed using magnetic selection, and the cells were split into fresh medium at 1:2. On day 8, a normalized number of transduced (CAR+) cells were plated on 96-well plates and treated with 20 μM ACZ or an equal volume of DMSO vehicle control in the absence or presence of antigen restimulation. The stimulation conditions were human Immunocult soluble CD3 / CD28 reagent (StemCell Technologies, catalog number 10971), K562 cells stably expressing CAR antigen CD19 at an E:T ratio of 1:1, or parental control K562 cells. After overnight incubation, CD19-Fc and then fluorescently labeled anti-human Fc antibodies were used to analyze the abundance of mbIL12 on transduced T cells by flow cytometry to detect surface CAR expression, anti-IL12p70, anti-CD45, anti-CD3, anti-CD4 and anti-CD8 antibodies. The geometric mean fluorescence intensity (GMFI) of IL12p70 in transduced cells was normalized relative to the gMFI of mbIL12 from untransduced cells treated identically (ligand+antigen restimulation), and its value was close to 1, which reflects the amount of undetectable mbIL12. Table 4 shows the change multiples of mbIL12 in restimulation conditions for a given construct, which is calculated as the gMFI of mbIL12 with added ligands divided by the gMFI in the absence of ligands.
[0239] Table 4. Expression constructs and their fold change in expression in transfected T cells
[0240]
[0241]
[0242] Human IL12p70 and / or human interferon-γMSD V-plex assay kit (Meso Scale Discovery) was used to measure the accumulated cytokines in the overnight culture supernatant of 40,000 transduced cells (CD19-CAR+) per 200 μL culture medium. For a given construct, the change fold of IL12 in restimulation conditions was calculated as the concentration of IL12 with added ligands divided by the concentration without ligands. All constructs were efficiently transduced and amplified in primary human T cells. Figure 3 , Fig. 9Tables 2 and 3 provide a list and schematic diagram of all constructs generated with the oligomerization domain. Fig. 9 and Table 3) were advanced to evaluation of expression and activity in T cells based on achieving low off-state and high regulation in HEK cells and T cells. All constructs containing the oligomerization domain reduced off-state (ligand-free) abundance of mbIL12 when compared to a similar construct without the oligomerization domain (construct CD19-IL12-192) ( Fig. 10A and Fig. 10B This regulation was largely maintained when observing the IL12 fraction shed into the supernatant ( Fig.11A and Fig. 11B ).
[0243] Example 7. Assessing Regulation of IL12 Activity Using STAT4 Phosphorylation on Bystander Natural Killer Cells
[0244] Fig.12 Depicted is a procedure for testing the engagement and function of IL12 with its receptor by measuring the phosphorylation of STAT4. Supernatant (100 μL) from cells plated on day 8 and harvested on day 9 was added to 40,000 natural killer (NK) cells (in 100 μL culture medium) derived from peripheral blood of matching donors. The NK cells were thawed from liquid nitrogen and left to stand overnight before the experiment was started. After 1 hour, the NK cells were stained with anti-CD56, anti-CD16, anti-CD45, and anti-CD3, and the STAT4 phosphorylation of the cells was evaluated. All constructs were efficiently transduced and amplified in primary human T cells (as described in Example 6). The columns of constructs generated with the CD19-CAR oligomerization domain are shown in Figure 2 C- Figure 2 E. The construct CD19-IL12-192 does not contain the oligomerization domain. Other controls included CD19-CAR alone (063), empty vector (EV), and untransduced (UT) cells. For non-shedding constructs (303-305), transduced cells were co-incubated with donor-matched NK cells (precipitate). All other samples tested were supernatants of cultured T cells. Fig.13A The regulation of pSTAT4 shown revealed that the regulation of the shedding fraction is functionally significant. Fig. 13B A standard curve showing the relationship between pSTAT MFI and IL12 concentration is shown.
[0245] Example 8. Oligomerization in the cytoplasmic environment: trimerization and tetramerization of FoxP3
[0246] HEK-293T cells were cultured in standard medium (DMEM (Fisher Scientific catalog number 11-960-044) with 10% FBS (Fisher Scientific catalog number 10-082-147) and 1% penicillin / streptomycin (P / S, ThermoFisher catalog number 15140122). Lipofectamine 2000 and 1 μg of Fig.14 Each of the plasmid DNAs of the FOXP3-X constructs shown (where X is variable) was transiently transfected into HEK293T cells. 100 μM acetazolamide was added one day after transfection, and the cells were cultured for another 1 day. mCherry was used as a transfection marker, and after checking the expression level by FAC, an equal number of transfected cells were precipitated and the cells were lysed using T-PER tissue protein extraction reagent (ThermoFisher catalog number 78510). The lysate was run on a NuPAGE 4-12% Bis-Tris gel (ThermoFisher catalog number NP0321BOX) and transferred to a nitrocellulose membrane (iBLOT2 NC conventional stack (ThermoFisher IB23001)). FoxP3 was detected using anti-FOXP3 monoclonal antibody (ThermoFisher Cat. No. MA5-16222) and IRDye 800CW goat anti-mouse IgG (LI-COR P / N 926-32210).
[0247] Example 9. Multiple TNFSF cytoplasmic tail-TM-hinge combinations
[0248] Multiple TNFSF cytoplasmic tail-TM-hinge combinations (from TWEAK, TRAIL, BAFF, GITRL and APRIL) trimerized with the collectin 7 trimerization domain were used to fine-tune the regulation of IL12. HEK-293T cells were cultured in standard medium (DMEM (Fisher Scientific catalog number 11-960-044) with 10% FBS (Fisher Scientific catalog number 10-082-147) and 1% P / S (ThermoFisher catalog number 15140122). Lipofectamine 2000 and 1 μg of ... Fig.14HEK293T cells were transiently transfected with plasmid DNA of each of the indicated IL12-X (where X was varied). 100 μM acetazolamide was added one day after transfection, and the cells were cultured for another day. mCherry was used as a transfection marker, and anti-IL12p40 / 70-V450 catalog number 561380 BD was used for IL12 staining.
[0249] Example 10. Use of other oligomerization domains such as tetramerization domains from hnRNPs
[0250] HEK-293T cells were cultured in standard medium (DMEM Fisher Scientific Catalog No. 11.960-044) with 10% FBS (Fisher Scientific Catalog No. 10-082-147) and 1% P / S (Thermo Fisher Catalog No. 15140122). Lipofectamine 2000 and 1 μg of Fig.14 Each of the plasmid DNAs of FOXP3-X (wherein X is variable) shown was transiently transfected into HEK293T cells. 100 μM acetazolamide was added after transfection for one day, and the cells were cultured for another 1 day. mCherry was used as a transfection marker, and after checking the expression level by FAC, an equal number of transfected cells were precipitated, and the cells were lysed using T-PER tissue protein extraction reagent (ThermoFisher catalog number 78510). The lysate was run on NuPAGE 4-12% Bis.Tris gel (ThermoFisher catalog number NP0321BOX) and transferred to a nitrocellulose membrane (iBLOT2 NC conventional stack (ThermoFisher IB23001)). FoxP3 was detected using anti-FOXP3 monoclonal antibody (ThermoFisher Cat. No. MA5-16222) and IRDye 800CW goat anti-mouse IgG (LI-COR P / N 926-32210).
[0251] Example 11. hDHFR-IL12 and hDHFR-IL2 constructs used to demonstrate the benefits of trimerization with existing oligomerization domains and alternative DRDs (hDHFR)
[0252] HEK-293T cells were cultured in standard medium (DMEM (Fisher Scientific catalog number 11-960-044) with 10% FBS (Fisher Scientific catalog number 10-082-147) and 1% P / S (ThermoFisher catalog number 15140122). Lipofectamine 2000 and 1 μg of Fig.14 HEK293T cells were transiently transfected with plasmid DNA of each of the indicated IL12-X (where X was varied). 100 μM acetazolamide was added one day after transfection, and the cells were cultured for another day. mCherry was used as a transfection marker, and anti-IL12p40 / 70-V450 catalog number 561380BD was used for IL12 staining.
[0253] In a similar experiment, HEK-293T cells were cultured in standard medium (DMEM (Fisher Scientific catalog number 11-960-044) with 10% FBS (Fisher Scientific catalog number 10-082-147) and 1% P / S (ThermoFisher catalog number 15140122). Lipofectamine 2000 and 1 μg of Fig.14 HEK293T cells were transiently transfected with plasmid DNA of each of the indicated IL2-X (where X was varied). 100 μM acetazolamide was added one day after transfection, and the cells were cultured for another day. mCherry was used as a transfection marker, and anti-IL2 antibody Biolegend catalog number 500311 was used for IL2 staining.
[0254] Example 12. Trimerization motif with IL2 payload
[0255] HEK-293T cells were cultured in standard medium (DMEM (Fisher Scientific catalog number 11-960-044) with 10% FBS (Fisher Scientific catalog number 10-082-147) and 1% P / S (ThermoFisher catalog number 15140122). HEK293T cells were transiently transfected with Lipofectamine 2000 and 1 μg of plasmid DNA for each of IL2-X (where X was varied) using the manufacturer's protocol. 100 μM acetazolamide was added one day after transfection, and the cells were cultured for another day. mCherry was used as a transfection marker, and anti-IL2 antibody (Biolegend catalog number 500311) was used for IL2 staining.
[0256] Example 13. Trimerization motif with IL15 payload
[0257] HEK-293T cells were cultured in standard medium (DMEM (V catalog number 11-960-044) with 10% FBS (V catalog number 10-082-147) and 1% P / S (ThermoFisher catalog number 15140122). HEK293T cells were transiently transfected with Lipofectamine 2000 and 1 μg of plasmid DNA for each of IL15-X (where X was varied) using the manufacturer's protocol. 100 μM acetazolamide was added one day after transfection, and the cells were cultured for another day. mCherry was used as a transfection marker, and IL15Ra-Fc-biotin (Catalog number ILA-82F4 Acrobiosystems) and then streptavidin BV421 (Biolegend, catalog number 405225) were used for IL15 staining.
[0258] Example 14. Use of heterotrimerization to regulate a single copy of a payload
[0259] Use Fig. 20 The indicated constructs IL12-266, 267 and 268 generated lentiviruses transduced Jurkat cells to 10%-15% positive as determined by using RQR8 as a transduction marker. Five days after transduction, cells were treated with 100 μM acetazolamide or DMSO and cultured for another day. RQR8 was detected using anti-CD34 clone QBEND10 (R&D catalog number FAB7227A), and IL12 was detected using anti-IL12p40 / 70-V450 (BD catalog number 561380). Fig.21A Shown are histograms showing IL12 levels in the presence and absence of acetazolamide. Fig. 21B is a schematic diagram showing the assembly and oligomeric state of DRD in IL12-266, 267 and 268. Fig. 21C Shown are the fold changes in IL12 geometric MFI following addition of drug to each of IL12-266, 267, and 268. As the transduced cells progressed from monomers, dimers, to trimers, they displayed a pattern of increasing fold regulation.
[0260] Example 15. Regulation of membrane-bound IL23 constructs in primary human CAR-T cells
[0261] On day 0, primary human T cells were stimulated with Dynabeads (T-expander CD3 / CD28) at a bead: cell ratio of 3:1 in medium containing 10% fetal bovine serum (FBS). The next day, lentivirus produced with constructs expressing CD19 CAR and membrane-bound oligomerized flexi-IL23 (CD19-IL23-002, CD19-IL23-003, CD19-IL23-004, CD19-IL23-005, CD19-IL23-006, CD19-IL23-007, CD19-IL23-008) and control constructs (CD19-IL23-001, which expresses secreted flexi-IL23; CD19-IL23-009, which expresses flexi-IL23 without any oligomerization regulatory hub) was added in the presence of reduced serum (5% FBS). On day 2, cells were diluted 1:2 with fresh 10% FBS medium. On day 5, cells were analyzed for CD19 CAR expression using CD19-Fc (R&D Systems, Minneapolis, MN; Part #9269-CD-050) and subsequently anti-human Alexa 647 anti-human IgG (Jackson ImmunoResearch, West Grove, PA; Part #109-607-003). The medium was replaced and the cells were treated with 100 μM acetazolamide or DMSO. Twenty-four hours later, T cells were analyzed by FACs. CD19 CAR was used as a transduction marker, and anti-IL12 / IL23p40-PE (Biolegend, SanDiego, CA; Catalog No. 501807) was used for IL23 expression staining. The geometric MFI of surface IL23p40 expression on CAR+ cells was plotted using Prism software. The results are shown in Fig. 22 . Analyze IL23 abundance in the presence and absence of ACZ. Cells transduced with some oligomerization constructs have low IL23 abundance (off state) in the absence of ACZ. The numbers above the cells treated with ACZ represent the fold change between the on state and the off state. The oligomerization constructs with multiple DRDs reduce the basal abundance of IL23 and enhance the fold change between the on state and the off state of IL23.
[0262] The following constructs were used in this example:
[0263]
[0264]
[0265]
[0266]
[0267]
[0268]
[0269]
[0270]
[0271]
[0272]
[0273]
[0274]
[0275]
[0276]
[0277]
[0278]
[0279]
[0280]
[0281]
[0282]
[0283]
[0284]
[0285]
[0286]
[0287]
[0288]
[0289]
[0290]
[0291] Example 16. Regulation of membrane-bound IFNα constructs in primary human CAR-T cells
[0292] On day 0, primary human T cells were stimulated with Dynabeads (T-expander CD3 / CD28) at a bead: cell ratio of 3: 1 in medium containing 10% fetal bovine serum (FBS). The next day, lentivirus produced with constructs expressing CD19 CAR and membrane-bound oligomeric IFNα (CD19-IFNα-002, CD19-IFNα-003, CD19-IFNα-004, CD19-IFNα-005, CD19-IFNα-006, CD19-IFNα-007, CD19-IFNα-008) and control constructs (CD19-IFNα-001, which expresses secreted IFNα; CD19-IFNα-009, which expresses monomeric IFNα without any oligomerization regulatory hub) was added in the presence of reduced serum (5% FBS). On day 2, cells were diluted 1:2 with fresh 10% FBS medium. On day 5, cells were analyzed for CD19 CAR expression using CD19-Fc (R&D Systems; Part #9269-CD-050) and subsequently anti-human Alexa 647 anti-human IgG (Jackson ImmunoResearch; Part #109-607-003). The medium was replaced and the cells were treated with 100 μM acetazolamide or DMSO. Twenty-four hours later, T cells were analyzed by FAC. CD19 CAR was used as a transduction marker, and anti-IFNα PE (BD Biosciences; Catalog No. 560097) was used for IFNα expression staining. The geometric MFI of surface IFNα expression on CAR+ cells was plotted using Prism software. The results are in Fig.23 . IFNα abundance was analyzed in the presence and absence of ACZ. Cells transduced with some oligomerized constructs had low IFNα abundance (off state) in the absence of ACZ. The numbers above the ACZ-treated cells indicate the fold change between the on state and the off state. The oligomerized constructs with multiple DRDs reduce the basal abundance of IFNα and enhance the fold change between the on state and the off state of IFNα. It is noteworthy that CD19-IFNα-009, which is configured as a non-oligomerized construct, becomes very abundant on the cell surface after being stabilized with ACZ, however, it does not have a low basal abundance similar to the oligomerized construct.
[0293] The following constructs were used in this example:
[0294]
[0295]
[0296]
[0297]
[0298]
[0299]
[0300]
[0301]
[0302]
[0303]
[0304]
[0305]
[0306]
[0307]
[0308]
[0309]
[0310]
[0311]
[0312]
[0313]
[0314]
[0315]
[0316]
[0317]
[0318]
[0319]
[0320]
[0321] Example 17. Regulation of IL2 from tandem CD19CAR-p2a-IL2 constructs in Jurkat cells
[0322] Jurkat, clone E6-1, cells were cultured in standard culture medium (RPMI+GlutaMAX supplement (Life Technologies; catalog number 61870127), fetal bovine serum (FBS) (Life Technologies; catalog number 10.082.147)). Jurkat cells were transduced with lentivirus produced by each of CD19CAR-IL2-001, CD19CAR-IL2-002, CD19CAR-IL2-003, CD19CAR-IL2-004, CD19CAR-IL2-005, CD19CAR-IL2-006, CD19CAR-IL2-007, CD19CAR-IL2-008 and IL2-017. Jurkat cells were transduced to 10-25% positive as determined by using CD19 CAR as a transduction marker. CD19 CAR expression was analyzed using CD19-Fc (R&D Systems; Part #9269-CD-050) and then anti-human Alexa 647 anti-human IgG (Jackson ImmunoResearch; Part #109-6 07-003). Five days after transduction, cells were treated with 100 μM acetazolamide or DMSO and cultured for another day. PE anti-human IL2 antibody (Biolegend; Catalog No. 500307) was used for IL2 expression staining. Fig.24 The geometric MFI indicating the IL2 abundance on CD19CAR positive Jurkat cells in the presence and absence of ACZ is shown. Note that cells transduced with some oligomerization constructs (CD19CAR-IL2-001, CD19CAR-IL2-002, CD19CAR-IL2-003, CD19CAR-IL2-004, CD19CAR-IL2-005, CD19CAR-IL2-006) have low IL2 abundance (off state) in the absence of ACZ, and the oligomerization concept explored in CD19CAR-IL2-007, CD19CAR-II2-008 is not significantly improved compared with IL2-017 (which is a construct regulated by non-oligomerization DRD). The numbers above the cells treated with ACZ represent the multiple of changes between the on state and the off state. MFI is calculated for cells in the CD19CAR positive gate. Oligomerized constructs with multiple DRDs reduced the basal abundance of IL2 and enhanced the fold change between the on and off states of IL2.
[0323] The following constructs were used in this example:
[0324] |Name CD19-IL2-001 (SEQ ID NO: 263)
[0325]
[0326] name CD19-IL2-002 (SEQ ID NO: 264)
[0327]
[0328] name CD19-IL2-003 (SEQ ID NO: 265)
[0329]
[0330] name CD19-IL2-004 (SEQ ID NO: 266)
[0331]
[0332] name CD19-IL2-005 (SEQ ID NO: 267)
[0333]
[0334]
[0335] name CD19-IL2-006 (SEQ ID NO: 268)
[0336]
[0337]
[0338] name CD19-IL2-007 (SEQ ID NO: 269)
[0339]
[0340]
[0341] name CD19-IL2-008 (SEQ ID NO: 270)
[0342]
[0343]
[0344] name IL2-017 (SEQ ID NO: 271)
[0345]
[0346]
[0347] Example 18. Oligomeric IL18 constructs
[0348] Table 5. Constructs used in Example 18
[0349]
[0350]
[0351]
[0352] T cell transduction
[0353] On day 1, primary human T cells were stimulated with Dynabeads (T-expander CD3 / CD28) at a 3:1 bead:cell ratio in medium containing 10% fetal bovine serum (FBS). The next day, T cells were transduced with IL18 oligomerization constructs using lentiviral vectors. On day 3, cells were diluted 1:2 with fresh 10% FBS medium. On day 4, cells were split 1:4 with fresh 10% FBS medium.
[0354] On day 6, cells were de-beaded and cultured at 1 × 10 6 Cells / mL were re-plated. The next day, cells were not stimulated or activated with soluble CD3 / CD28 (StemCell Technologies) and treated with 50 μM acetazolamide (ACZ) or DMSO. After 24 hours, anti-IL18 (clone 159-12B, MBL Int catalog number D045-3) and PE-conjugated anti-rat IgG2a (Biolegend, catalog number 407508) were used to detect membrane-bound IL18 by flow cytometry. Human IL18 MSD V-plex assay kit (Meso Scale Discovery) was used to measure the cytokines accumulated for 24 hours in culture supernatants (from 200,000 cells per 200 μL culture medium).
[0355] Fig.25 is a schematic diagram showing the experimental design for determining IL18 expression, and Fig.26 is a schematic diagram showing the experimental design for determining IFNγ release. Fig. 27 , Fig.28 , Figure 31-32 , Figure 33-35 , Figure 38-45 , Figure 52-53 The frequency of T cells expressing IL18 in the presence and absence of ACZ is shown. Figure 38-40 , Numbers above ACZ-treated cells indicate the fold change between the on and off states in the presence or absence of ACZ. Figure 27-33 , Figure 35-37 and Figure 41-54In the figure, the graph with open circles refers to the left y-axis and shows IL18 released into the supernatant. IL18 constructs containing a hinge with a defined shedding site result in an expanded dynamic range for regulation of the shed IL18 fraction in the cell supernatant.
[0356] Antigen-independent interferon-γ release
[0357] On day 1, primary human T cells were stimulated with Dynabeads (T-expander CD3 / CD28) at a 3:1 bead:cell ratio in medium containing 10% fetal bovine serum (FBS). The next day, T cells were transduced with IL18 oligomerization constructs using lentiviral vectors. On day 3, cells were diluted 1:2 with fresh 10% FBS medium. On day 4, cells were split 1:4 with fresh 10% FBS medium.
[0358] On day 6, cells were debeaded and cultured at 1 × 10 6 Cells / mL were re-plated and left to stand for 48 hours. On the 8th day, cells were re-plated with 200,000 cells / 200 μL culture medium and treated or not treated with recombinant 20 ng / mL human IL15 (Biolegend, catalog number 570304). Interferon (IFN)-γ and IL18 accumulated for 48 hours in the culture supernatant were measured using a customized human IFNγ / IL18 MSD V-plex assay kit (Meso Scale Discovery).
[0359] Fig.29 , Fig.30 , Fig.36 , Fig.37 , Figures 46-51 and Fig.54 is a graph showing the amount of IFNγ released from transduced T cells treated or untreated with recombinant IL 15. The circles refer to the right y-axis and show the amount of IL18 released into the supernatant.
[0360] Jurkat transduction
[0361] Jurkat, clone E6-1, cells (ATCC) were cultured in standard culture medium (RPMI+GlutaMAX supplement: Life Technologies catalog number 61870036, fetal bovine serum (FBS) Life Technologies catalog number A38400-01). Jurkat cells were transduced with a lentiviral vector containing an IL18 oligomerization construct. Five days after transduction, cells were treated with 50 μM acetazolamide or DMSO, and the cells were cultured for another day. Membrane-bound I-18 was detected by flow cytometry using anti-IL18 (clone 159-12B, MBL Int catalog number D045-3) and PE-conjugated anti-rat IgG2a (Biolegend, catalog number 407508).
[0362] Fig.55 Flow cytometry histograms are shown indicating changes in mbIL18 expression levels on Jurkat cells in the presence and absence of ACZ. Numbers above ACZ-treated cells indicate the fold change between IL18 levels observed in the presence and absence of ACZ (on vs. off states). MFI was calculated for cells within the mCherry gate.
[0363] In summary, mbIL18 synergized with mbIL15 or recombinant IL15 to induce IFNγ release in T cells. The IL18 constructs IL18-037 and IL18-042 showed 2- to 3-fold modulation and the ability to synergize with recombinant IL15 to induce IFNγ release in T cells. The IL18-042 construct also showed IL18 activity in the culture medium collected from transduced activated cells, supporting potential pleiotropic effects.
[0364] Example 19. Pharmacologically controlled expression of membrane-bound IL12 leads to T cell therapy with enhanced efficacy in preclinical solid tumor models
[0365] Table 6. Constructs used in Example 19
[0366]
[0367] Constructs 333 and 345 were characterized in vitro. Figure 56-61Geometric MFIs indicating IL12 abundance on the surface of CAR-T cells transduced with control (192) and IL12 constructs (302, 333, 345) are shown, demonstrating modulation of IL12 function and demonstrating that basal off-state levels of IL12 constructs containing collectin 7 oligomerization domains are lower than control monomer constructs. Also shown are IL12 shedding levels detected using a Meso-scale discovery (MSD) assay and the activity of shedding components on NK cells. Figures 56-58 is a set of graphs showing that in resting T cells, collectin-7 trimerization constructs have a low off state with modulation of shed IL12 levels ( Fig.57 ), which demonstrated functional activity on bystander natural killer (NK) cells ( Fig.58 ). Figure 59-61 is a set of graphs showing that in activated T cells stimulated with CD3 / CD28 for 20 hours, IL12 constructs containing the collectin-7 trimerization domain exhibit a low basal off-state with regulated shed IL12 levels ( Fig.60 ) and in vitro functional activity against bystander NK cells (phosphorylation of STAT4) ( Fig.61 ).
[0368] For in vivo studies, NOD SCIDγ mice were implanted intravenously with 100,000 cells from a CD19+ Raji Burkitt lymphoma cell line stably expressing luciferase to track tumor growth. Three (3) days after tumor implantation, mice were randomized into treatment groups with equal tumor burden. Four days after tumor implantation, CD19-CAR-T cells carrying various IL12 constructs were treated with different cell doses via adoptive cell transfer (ACT). Mice were bled 7 days after ACT to provide a baseline for cytokine levels and cell expansion, and then ACZ was administered to mice by oral gavage. Fig.62 ACZ dosing and bleeds were continued as described until the end of the study at day 16 post-ACT. IL12 was modulated on the surface of CD19+ cells, with constructs 302, 333, and 345 showing a greater ability to modulate surface abundance compared to the control monomer construct 192. Similarly, IL12 in plasma was modulated with constructs 302, 333, and 345, but not with the control construct, showing up to 54x modulation with ACZ.
[0369] As shown in Figures 63 and 64, IL12 is regulated in vivo. Figure 63 shows that IL12 is regulated on the surface, and Fig.64IL12 is also shown to be regulated in plasma. Figure 63 shows that IL12 is regulated on the surface of CD19+ cells, where constructs 302, 333, and 345 show a greater ability to regulate surface abundance than the control monomer construct 192. Similarly, Fig.64 IL12 in plasma was shown to be regulated with the 302, 333, and 345 constructs, but not with CAR alone (063 construct) or the monomer control (192 construct), showing up to 54x regulation with ACZ.
[0370] For the scRaji study, 5 million Raji cells-CD19+Burkitt lymphoma cell lines were implanted subcutaneously in NOD SCIDγ mice. 13 days after tumor implantation, mice were randomly divided into treatment groups with equal tumor volumes (measured using digital calipers). Fourteen (14) days after tumor implantation, control construct 063 (CAR alone), EV (empty vector) or CD19-CAR-T cells modified with construct 345 were administered for adoptive cell transfer (ACT). Mice began to receive continuous daily dosing of ACZ or vehicle on the same day as ACT. Mice were bled and measured as described in the study design ( Fig.65 ). Cell proliferation and phenotype were measured in the blood using flow cytometry, and cytokine levels in plasma were determined using the Meso Scale Discovery assay. Mice were euthanized when tumor volume endpoints (2000 mm3), hind limb paralysis, or evidence of graft-versus-host disease were reached. Animals administered CAR-T cells containing construct 345 showed efficacy in the switched-on state and the ability to control large solid tumors. Subcutaneous Raji tumors were measured twice a week using a digital caliper. Mice treated with CAR-T cells modified with construct 345 showed efficacy (in terms of tumor burden) regulated by ACZ at a dose 10x lower than cells modified with only CAR control construct 063 ( Figures 66-68 ). Figures 66-68 We showed that infusion of CAR-T cells expressing central IL12 (construct 345) provided regulated antitumor activity at suboptimal CAR-T cell doses.
[0371] For PMEL studies (Figures 69-78), 500,000 B16-F10 (PMEL antigen positive) melanoma cells were implanted subcutaneously into C57BL / 6 mice. Thirteen days after tumor implantation, mice were randomized into treatment groups with equal tumor burden (measured using digital calipers) and the endogenous immune system was depleted using intravenous cyclophosphamide. Fourteen (14) days after tumor implantation, PMEL antigen-specific T cells with or without IL12 armoring were treated with an alternative mouse IL12 construct via adoptive cell transfer (ACT). Mice received continuous daily dosing of ACZ or vehicle starting on the day of ACT. Fig.65 As shown in Figure 69-72, mice are bled and measured. Flow cytometry is used to measure cell expansion and phenotype in blood, and MSD assay is used to determine cytokine levels. On the 7th day after ACT, tumor, spleen and tumor draining lymph node (TDLN) are harvested, digested and analyzed using flow cytometry. Meso Scale Discovery assay is used to determine the cytokine levels in the tumor after digestion. The regulated mbIL12 constructs of the alternative mouse analogs of people's construct 333 show IL12 and IFNγ to the localization in tumor and IL12 and IFNγ in blood plasma regulation. The regulation and control center IL12 construct enables to regulate the IL12 in blood plasma and tumor. In the animals of the Pmel cells engineered with the regulation and control center IL12 construct, IL12 and IFNγ levels are compared with the secretion of non-regulated (lacking DRD CA2) or membrane-bound IL12 and show a greater degree of localization (the ratio of tumor to plasma cytokines is larger). This ACZ-driven IL12 modulation using a regulatory hub IL12 construct was shown to regulate the frequency of circulating DCs ( Fig.73 ), phenotype of activated monocytes in circulation ( Fig.74 ) and showed functional impact in terms of secretion of IL12 and IFNγ levels in tumors but not systemically (Figures 69-72). Fig.73 and Fig.74 As shown, MHC II monocytes from the study at day 14 post-ACT indicate that ACZ-induced regulation of IL12 in the presence of constructs with regulatory hubs results in a regulated phenotype (MHCII+ activated monocytes) in the circulation. Figures 75-78As shown, the phenotype of the intratumoral and systemic myeloid populations of animals receiving Pmel cells transduced with a regulatory central IL12 construct showed M1 to M2 and phenotypic conversion in the same tumor microenvironment as animals receiving Pmel cells transduced with a secreted non-regulated IL12 construct. Compared with secreted or constitutive mbIL12, these phenotypic changes of the regulatory central IL12 are more localized (occurring more at the tumor site rather than in the spleen or lymph nodes), as demonstrated by the upregulation of PD-L1 on myeloid cell populations in the spleen and TDLN, but the degree of upregulation of PD-L1 in the spleen is similar.
[0372] In summary, when using membrane-bound regulated constructs, IL12 was mostly localized in the tumor, while regulated IL12 and IFNy were observed throughout the body. In the blood, regulated central IL12 was found to have functional effects. The on-state IL12 levels (in plasma and tumors) produced by adoptively transferred Pmel cells engineered with central IL12 constructs were closer to the IL12 levels in animals receiving Pmel cells expressing the constitutive mbIL12 construct than the IL12 levels in animals in which the central IL12 was in the off state (no ACZ dose). Similarly, in animals receiving Pmel cells engineered with central IL12, phenotypes such as MHCII expression on circulating monocytes were also regulated by ACZ ( Fig.74 Functional effects have also been observed in the tumor microenvironment (TME). For example, regulated central IL12 promotes macrophage M1-M2 phenotype switching to a similar extent as unregulated secreted IL12 ( Fig.77 ). However, unregulated secreted IL12 systemically produces different effects than regulated central IL12. For example, unregulated secreted IL12 leads to significantly greater expression of PD-L1 on dendritic cells and myeloid-derived suppressor cells (MDSCs) in the spleen and lymph nodes compared with regulated central IL12 ( Fig.78 ).
[0373] Example 20. IL12 constructs with PDE5
[0374] Table 7. Constructs used in Example 20
[0375]
[0376] Three oligomerization concepts were tested using PDE5 as the DRD. Two control constructs, IL12-229 and IL12-235, were included in the test. In IL12-274, IL12 was fused directly to CD40L and the natural shedding site of CD40L was eliminated. IL12-275 used the DAP12 transmembrane hinge. IL12-276 was oligomerized with collectin 7 helical trimers, except that collectin 7 was placed intracellularly. Fig.79 and 80 Flow cytometric analysis shown demonstrates similar performance to the oligomerized CA2DRD-IL12 fusion, but with reduced basal abundance.
[0377] Example 21. Regulation of IFNα in tumor infiltrating lymphocytes in combination with constitutively membrane-bound IL15 (mbIL15)
[0378] Table 8. Constructs used in Example 21
[0379]
[0380]
[0381] Tumor infiltrating lymphocytes (TILs) were isolated from tumors, expanded, and transduced with a control construct containing only membrane-bound IL15 (mbIL15) (Construct 292) and a construct containing constitutive mbIL15 and a CA2-regulated centrally regulated form of IFNα (Construct 016). The transduced cells (500,000) were transferred to a GREX apparatus and allowed to expand for 2 weeks according to a rapid expansion protocol in the presence or absence of 25 μM ACZ. At the end of those 2 weeks, TILs were analyzed for IFNα surface abundance using flow cytometry (BD Biosciences Catalog No. 560097). Results are presented in Fig.81 and 82 These figures show the geometric median fluorescence intensity (geoMFI) indicating the abundance of membrane-bound IFNα on the surface of tumor-infiltrating lymphocytes transduced with control (construct 292) and IFNα experimental (construct 016) constructs, demonstrating the regulation of IFNα by the addition of ACZ throughout the rapid expansion protocol. The regulation on the last day of TIL expansion is shown.
[0382] for Figures 83-85On day 7, primary human T cells were stimulated with Dynabeads (T-expander CD3 / CD28) at a bead:cell ratio of 3:1 in medium containing 10% fetal bovine serum (FBS). The next day, T cells were transduced with IL15-IFNα oligomerization constructs using lentiviral vectors. On day 5, cells were diluted 1:2 with fresh 10% FBS medium. On day 4, cells were split 1:2 with fresh 10% FBS medium. On day 1, cells were debeaded and cultured at 1×10 6 Cells were replated at 500,000 cells / mL and left to stand for 24 hours. On day 0, cells were replated at 500,000 cells / 1000 μL of medium and treated or untreated with 50 μM ACZ. The expression of membrane-bound IL15 and membrane-bound IFNα was measured on days 3, 7, 10, 14, and 20. Figures 83-85 As shown, the accumulation of mbIL15-expressing cells and IFNα over time was regulated approximately 20-fold in the IFNα-016 and IFNα-018 constructs.
[0383] In another round of experiments, human TILs were expanded and engineered with lentiviral vectors to express IL15, IL18 (IL1 family members) (see Example 18) or TNFSF-X (TNF superfamily members) with IFNα. The amplified TILs were immunophenotyped and evaluated for multifunctionality by flow cytometry after CD3 / CD28 stimulation. The engineered TILs were transferred to NSG mice to evaluate the persistence of antigen-independent TILs in the absence of exogenous IL2. The protein level control of cytokines modified with our drug response domain (DRD) based on carbonic anhydrase 2 (CA2) in the presence of CA2 ligand acetazolamide (ACZ) was evaluated. Cytokine expression was evaluated in flow cytometry and Meso Scale Discovery assays.
[0384] Engineered TILs expressing IL15 and IFNα, IL18, or TNFSF-X simultaneously showed similar expansion multiples, immunophenotypes, and versatility in vitro to TILs expressing only IL15. TILs expressing combined cytokines showed similar in vivo antigen-independent persistence to TILs engineered only with IL15 in the absence of IL2. Suboptimal cell doses of T cells expressing IL15 and IFNα or IL18 simultaneously showed improved efficacy and TME remodeling compared to control cells, while combining IL15 with TNFSF-X resulted in significant tumor growth arrest of B16 melanoma tumors without escape.
[0385] IL15 drives the expansion and persistence of IL2-free cytoTIL15TM cells, and the addition of pleiotropic and highly immunostimulatory members of the IFN, IL1, or TNF families provides enhanced efficacy for patients with solid tumors marked by an immunosuppressive TME.
[0386] Example 22. IL18 constructs transduced by Jurkat.
[0387] Table 9. Constructs used in Example 22.
[0388]
[0389]
[0390] Test plan such as Fig.86 As shown. Figures 87-90 As shown, mbIL18 was regulated 10x in the IL18-080 construct. In constructs IL18-076 and IL18-082, released IL18 was regulated approximately 2x. All constructs with collectin 7 showed very low IL18 basal and no / low regulation, which may be due to low mbIL18 expression below our detection range. The constructs containing VEFGR showed particularly good regulation in the 100 μl virus titration, where this construct had the lowest basal and for IL18-080, regulation was up to 10x.
[0391] Table 10. Comparison of IL18 fold changes.
[0392]
[0393]
[0394] Example 23. Oligomerization in the cytoplasmic environment: trimerization and tetramerization of SOX2
[0395] HEK-293T cells were cultured in standard medium (DMEM (Fisher Scientific catalog number 11-960-044) with 10% FBS (Fisher Scientific catalog number 10-082-147) and 1% penicillin / streptomycin (P / S, ThermoFisher catalog number 15140122). Lipofectamine HEK293T cells were transiently transfected with 2000 and 1 μg of plasmid DNA of each of the SOX2-001 to SOX2-006X constructs (where X was varied) as shown in Table 12 below. Constructs SOX2-001 and SOX2-002 were not oligomerized. Constructs SOX2-003 and SOX2-005 were trimerized with collectin 7 at the N-terminus (SOX2-003) or C-terminus (SOX2-005). Similarly, SOX2-004 and SOX2-006 were trimerized with collectin 7 from Helical tetramerization of Kv7.4. 100 μM acetazolamide was added one day after transfection, and the cells were cultured for another day. mCherry was used as a transfection marker for SOX2-001 and SOX2-002, and GFP was used as a transfection marker for SOX-003 to SOX2-006, and after checking the expression level by FAC, an equal number of transfected cells were pelleted and lysed with T-PER tissue protein extraction reagent (ThermoFisher catalog number 78510). The lysate was subjected to NuPAGE The samples were run on a 4-12% Bis-Tris gel (ThermoFisher catalog number NP0321BOX) and transferred to a nitrocellulose membrane (iBLOT2 NC conventional stack (ThermoFisher IB23001)). SOX2 was detected using anti-FOXP3 SOX2 monoclonal antibody (RnD catalog number AF2018-SP) and IRDye 800CW goat anti-mouse IgG (LI-COR P / N 926-32210). The results are shown in Fig.91 and Table 11. Jurkat cells were successfully transduced with the SOX2 construct.
[0396] Table 11. Transduction efficiency of SOX2 constructs.
[0397] Transduction efficiency SOX2-001 26.5% SOX2-002 20.2% SOX2-003 26.0% SOX2-004 32.4% SOX2-005 34.7% SOX2-006 38.7%
[0398] Table 12. Constructs used in Example 23
[0399]
Claims
1. An engineered regulatable polypeptide monomer comprising (a) at least one biologically active payload; (b) at least one drug response domain (DRD), wherein the DRD is operably linked to the payload, and wherein the at least one DRD is responsive to a ligand; and (c) an oligomerization domain configured to promote oligomerization of the polypeptide monomers.
2. The engineered regulatable polypeptide monomer of claim 1, wherein the biological activity of the at least one payload is regulated by the interaction of the at least one DRD with an effective amount of the ligand.
3. An engineered regulatable polypeptide monomer as described in claim 1 or 2, wherein the oligomerization domain is selected from a dimerization domain, a trimerization domain, a tetramerization domain, a pentamerization domain and a hexamerization domain.
4. An oligomer comprising at least two engineered regulatable polypeptide monomers as described in any one of claims 1-3, wherein the monomers are connected by the oligomerization domains of the monomers.
5. The oligomer of claim 4, comprising at least three engineered regulatable polypeptide monomers of any one of claims 1-3, wherein the monomers are connected via the oligomerization domains of the monomers.
6. The oligomer of claim 4 or 5, wherein the monomers are non-covalently linked via the oligomerization domain of each of the monomers.
7. The oligomer of claim 4 or 5, wherein the at least one payload of each of the monomers is a payload, wherein the one payload of each of the monomers is the same, wherein the DRD of each of the monomers is a DRD, and wherein the one DRD of each of the monomers is responsive to the same ligand.
8. An oligomer as described in any of claims 4-7, wherein the at least one payload is a first payload, wherein the first payload in each of the monomers is the same, wherein the biological activity of the first payload in the oligomer has a range spanning from a basal activity level in the absence of a ligand to a maximum activity in the presence of a saturating amount of a ligand, and wherein the basal activity level of the first payload in the oligomer is lower than the basal activity level of the same payload in a control construct.
9. An oligomer as described in any of claims 4-8, wherein the at least one payload is a first payload, wherein the first payload in each of the monomers is the same, wherein the biological activity of the first payload in the oligomer has a range spanning from a basal activity level in the absence of a ligand to a maximum activity in the presence of a saturating amount of a ligand, and wherein the range of activity of the first payload in the oligomer is greater than the range of activity of the same payload in a control construct.
10. An engineered regulatable polypeptide comprising (a) at least one biologically active payload; and (b) a regulatory hub comprising at least two drug response domains (DRDs), wherein the regulatory hub is operably linked to the payload, wherein the at least two DRDs are responsive to a ligand.
11. The engineered regulatable polypeptide of claim 10, wherein the biological activity of the payload is regulated by the interaction of the at least two DRDs with an effective amount of the ligand.
12. The engineered regulatable polypeptide of claim 10 or 11, wherein the at least two DRDs are responsive to the same ligand.
13. The engineered regulatable polypeptide of claim 12, wherein the regulatory hub comprises three DRDs, and wherein the three DRDs are responsive to the same ligand.
14. An engineered regulatable polypeptide as described in any one of claims 10-13, wherein the biological activity of the at least one payload ranges from a basal activity level in the absence of the ligand to a maximum activity level of the payload in the presence of a saturating amount of the ligand, and wherein the range of activity levels of the payload in the engineered regulatable polypeptide is greater than the range of activity levels of the same payload in a control construct.
15. The engineered regulatable polypeptide of any one of claims 10-14, wherein the payload has a basal level of biological activity in the absence of a ligand that is lower than the basal level of biological activity of the same payload in a control construct.
16. An engineered regulatable oligomer comprising at least two polypeptide monomers, wherein each monomer comprises at least one payload or one DRD, wherein the oligomer comprises at least one payload operably linked to at least two DRDs, wherein the at least one payload has biological activity, wherein the at least two DRDs are responsive to a ligand.
17. An engineered regulatable oligomer as described in claim 16, wherein each of the at least two polypeptide monomers comprises an oligomerization domain, and wherein the oligomerization domain of one of the polypeptide monomers comprises a heterologous oligomerization domain.
18. The engineered regulatable oligomer of claim 16 or 17, wherein the at least two DRDs are responsive to the same ligand.
19. An engineered regulatable oligomer as described in any of claims 16-18, wherein the biological activity of the effective load in the oligomer has a range spanning from a basal activity level in the absence of a ligand to a maximum activity in the presence of a saturating amount of a ligand, and wherein the basal activity level of the oligomer is lower than the basal activity level of the same effective load in a control construct.
20. The engineered regulatable oligomer of claim 17, wherein the at least two polypeptide monomers comprise a first polypeptide monomer, a second polypeptide monomer, and a third polypeptide monomer, wherein the first polypeptide monomer and the second polypeptide monomer are identical, wherein each of the first polypeptide monomer and the second polypeptide monomer comprises a DRD, and wherein the third polypeptide monomer comprises a hetero-oligomerization domain and a payload.
21. The engineered regulatable oligomer of any one of claims 16-20, wherein the ratio of the payload to DRD in the oligomer is 1:
1.
22. An expressible nucleic acid construct encoding one or more engineered regulatable polypeptide monomers as described in any one of claims 1-3, one or more engineered regulatable polypeptides as described in any one of claims 10-14, or one or more polypeptide monomers of an oligomer as described in any one of claims 16-19.
23. A plurality of expressible nucleic acid constructs, each of which encodes an engineered regulatable polypeptide monomer as described in any one of claims 1-3, one or more engineered regulatable polypeptides as described in any one of claims 10-14, or one or more polypeptide monomers of an oligomer as described in any one of claims 16-19.
24. A vector comprising one or more expressible nucleic acid constructs according to claim 16.
25. A cell comprising one or more expressible nucleic acid constructs according to claim 16.
26. The cell of claim 25, wherein the cell expresses at least two polypeptide monomers, and wherein the at least two polypeptide monomers form an oligomer.
27. The cell of claim 26, wherein the oligomer comprises at least three polypeptide monomers.
28. A cell comprising the vector of claim 24.
29. The cell of any one of claims 25-28, wherein the cell is a human cell.
30. The cell of claim 29, wherein the human cell is an immune cell.
31. The engineered regulatable polypeptide monomer of any one of claims 1-3; the engineered regulatable polypeptide of claims 10-14; the engineered expressible oligomer of claims 16-19; the expressible nucleic acid construct of claim 16; the vector of claim 24; or the cell of any one of claims 25-31, wherein the DRD is selected from CA2 (SEQ ID NO: 1), ecDHFR (SEQ ID NO: 18), hDHFR (SEQ ID NO: 37), FKBP (SEQ ID NO: 93), PDE5 ligand binding domain (SEQ ID NO: 94), PDE5 (SEQ ID NO: 95) and ER (SEQ ID NO: 96), and / or an amino acid sequence having at least 85% identity to SEQ ID NO: 1, 18, 37, 93, 94, 95 or 96.
32. An engineered regulatable polypeptide monomer as described in any one of claims 1-3, an engineered regulatable polypeptide as described in claims 10-14, an expressible nucleic acid construct as described in claim 16, a vector as described in claim 24, or a cell as described in any one of claims 25-29, wherein the payload is selected from the group consisting of: cytokines, cytokine receptors, TCR, CAR, immune regulatory proteins, and combinations thereof.
33. A method for regulating the amount or activity of a payload in an oligomer as described in any one of claims 4-9 or an engineered regulatable polypeptide as described in claims 10-15, comprising contacting a DRD with a selected dose of a ligand, wherein the selected dose of the ligand results in a selected amount or activity level of the payload.
34. A method of regulating the amount or activity of at least two payloads in an engineered regulatable oligomer as described in any of claims 16-19, comprising contacting at least two DRDs with a ligand, wherein a selected dose of the ligand results in a selected amount or activity level of the at least two payloads.
35. The method of claim 33 or 34, wherein the contacting is performed in vivo.
36. A method of delivering a payload to a subject, comprising administering to the subject the nucleic acid construct of claim 16 or the vector of claim 24.
37. A method of delivering a payload to a subject, comprising administering to the subject a plurality of expressible nucleic acid constructs as claimed in claim 23.
38. The method of claim 36 or 37, further comprising administering to the subject a selected amount of a ligand to deliver a selected amount or activity of the payload to the subject.
39. The method of any one of claims 36-38, wherein the expression of two or more nucleic acid constructs in the cells of the subject results in the expression of two or more polypeptide monomers, wherein the two or more polypeptide monomers form oligomers.
Citation Information
Cited By
Pig CD40L tripolymer protein, recombinant bacillus subtilis for expressing protein and application
CN122325580A
